Introduction {#s1}
============

Most complex diseases are associated with a tissue-specific chronic inflammation. Excessive inflammation has deleterious consequences, characterized by tissue damage and disease onset ([@bib42]; [@bib27]; [@bib45]). Understanding cellular and molecular mechanisms that can keep inflammation in check will have important therapeutic implications in autoimmune and inflammatory diseases. Macrophages, especially tissue-resident populations (TRMs) represent a key constituent of the innate immune system in orchestrating inflammation and influencing the functions of other immune and non-immune cells ([@bib42]; [@bib12]). In concert with other innate immune cells (e.g., mast cells), macrophages sense environmental stimuli and subsequently instruct adaptive immunity (primarily T cells), together to elicit the processes of host defense and tissue repair ([@bib34]).

Under autoimmune conditions, self-reactive T cells accumulate at tissue sites and lead to tissue destruction. T cell activities need to be restrained to maintain immunological tolerance ([@bib49]). However, how these autoimmune T cell responses are influenced by tissue microenvironment remains poorly understood. We hypothesize that macrophages, especially TRMs may fulfill such a role to modulate tissue T cell activities. Multiple mechanisms may be exploited by these TRMs to regulate T cell activities. First, these TRMs express multiple coinhibitory molecules of B7/CD28 and TNFR families, such as PD-L1, PD-1 and TIM-4 (refs \[[@bib38]; [@bib25]; [@bib54]\]). Second, TRMs may regulate the generation, stability, and function of Foxp3^+^ regulatory T (Treg) cells. This notion is supported by a few studies ([@bib13]; [@bib52]; [@bib29]). These studies have demonstrated that macrophages residing in the lung ([@bib52]), or intestinal lamina propria ([@bib13]; [@bib29]) can promote the generation of Treg cells. These two mechanisms are not mutually exclusive, because certain coinhibitory molecules (e.g., PD-L1) have been found to promote the generation of Treg cells ([@bib20]; [@bib59]; [@bib1]).

Recently, a new subset of TRMs has been identified ([@bib32]; [@bib58]; [@bib22]). These macrophages are phenotypically characterized as CD11b^+^ F4/80^hi^ CRIg^+^. CRIg^+^ macrophages can be detected in peritoneal cavity and most digestive organs, including pancreas, liver, small and large intestines ([@bib32]; [@bib58]; [@bib22]; [@bib24]). Macrophages from lymphoid organs do not express CRIg. CRIg is also absent in other immune cells, including T cells, B cells, NK cells, dendritic cells, monocytes, and neutrophils ([@bib32]; [@bib58]). Thus, the expression of CRIg is restricted to TRMs. CRIg (gene symbol: *Vsig4*) was previously reported as a complement receptor ([@bib32]). It binds to complement components C3b, iC3b and C3c, and is involved in the phagocytosis of microbes ([@bib32]; [@bib60]). However, further studies including ours, have revealed that CRIg can function as a coinhibitory molecule of the B7/CD28 superfamily ([@bib58]; [@bib22]). In this regard, CRIg potently suppresses T cell proliferation and cytokine production ([@bib58]; [@bib22]). Given that CRIg is exclusively expressed by TRMs, we propose that CRIg mediated signaling represents a tissue-derived mechanism by which resident macrophages regulate tissue homeostasis and inflammatory processes.

In autoimmune type 1 diabetes (T1D), islet inflammation (insulitis) is exacerbated by the loss-of-balance between regulatory and pathogenic immune cells ([@bib6]). However, not all individuals with insulitis proceed to become diabetic, suggesting that there exist mechanisms that can keep insulitis in check. We have previously found that the abundance of CRIg^+^ macrophages in the pancreas was negatively correlated with the risk of diabetes onset in non-obese diabetic (NOD) mice, the primary animal model for T1D. More importantly, in vivo administration of CRIg-Ig fusion protein suppressed diabetes in these mice ([@bib22]). In this study, we attempted to understand how CRIg impacts T cell activities using mouse T1D as a primary model system. Our studies revealed a dual role of CRIg in regulating effector T cell proliferation and Treg differentiation and stability. Together, these two outcomes led to a reinforced immune tolerance in NOD mice. Furthermore, we investigated the role of gut microbiota and derived metabolites in regulating the expression of CRIg in TRMs. Together, these findings support a new model of immune regulation in tissue homeostasis whereby environmental cues instruct TRMs to express CRIg, which functions as an immune checkpoint molecule to regulate adaptive immunity and promote immune tolerance.

Results {#s2}
=======

CRIg^+^ TRMs form a protective barrier surrounding pancreatic islets to prevent autoimmune infiltration in NOD mice {#s2-1}
-------------------------------------------------------------------------------------------------------------------

CRIg is exclusively expressed in TRMs ([@bib32]; [@bib58]; [@bib22]). CRIg^+^ macrophages can be detected in most digestive organs at steady state, including the pancreas, liver, colon and peritoneal cavity of both C57BL/6 (B6) and NOD mice ([Figure 1-figure supplement 1A, B](#fig1s1){ref-type="fig"} and data not shown). CRIg^+^ cells was also found in human pancreas ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). There was no CRIg^+^ cell in the lung in both mouse strains ([Figure 1---figure supplement 1A and B](#fig1s1){ref-type="fig"} and data not shown). The expression of CRIg was not detected in lymphoid-lineage cells, including T cells, B cells and NK cells ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). In the pancreas, CRIg^+^ TRMs were enriched at the capsular area of the islets ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}), exhibiting a perivascular distribution ([@bib22]). We have previously found that the abundance of islet CRIg^+^ macrophages in NOD mice was negatively correlated with the risk of diabetes onset in these animals ([@bib22]), suggesting a disease-suppressing role of CRIg^+^ TRMs in T1D. However, the mechanisms remained undefined. Given the unique tissue distribution pattern of these cells, we examined the relationship between the severity of insulitis and the abundance of peri-islet CRIg^+^ TRMs on a per-islet basis in pre-diabetic NOD mice. We found that intact islets (free from autoimmune infiltration) were associated with more abundant peri-islet CRIg^+^ TRMs. In contrast, in insulitic islets, there was a lack of CRIg expression in TRMs, especially in those peri-islet areas succumbed to infiltration ([Figure 1A](#fig1){ref-type="fig"}). These results suggest that CRIg^+^ TRMs may function as a local barrier to prevent immune infiltration into pancreatic islets. We proposed that CRIg molecule was critical for these TRMs to exhibit such a protective role in insulitis. To confirm the role of CRIg, we generated CRIg-null mutation onto a NOD background. Indeed, genetic ablation of CRIg significantly exacerbated the severity of insulitis, reflected by a massive infiltration of leukocytes in most islets ([Figure 1B](#fig1){ref-type="fig"}), supporting a critical role of CRIg for these CRIg^+^ TRMs to suppress insulitis. This was consistent with our previously published observations showing that the lower the number of pancreatic CRIg^+^ TRMs, the higher the incidence of diabetes in NOD mice ([@bib22]).

![CRIg^+^TRMs form a protective barrier to prevent tissue autoimmune infiltration and activation.\
(**A**) The distribution of CRIg^+^ TRMs within the pancreas. Immunostaining of pancreatic frozen sections of 10-week-old NOD mice. (left) Representative images depicting an intact (upper) and an insulitic (lower) islet, respectively. Red: CRIg; Blue: DAPI. The border of the islet was marked by dotted lines; immune infiltration was highlighted by higher density of DAPI^+^ dots (n = 9 for intact and n = 8 for insulitic). Bar, 50 um. (right) The numbers of CRIg^+^ TRMs per islet counted from immunostaining sections of pancreas as in (**A**). Islets were categorized into intact (free from infiltration) and insulitic groups. (**B**) The severity of insulitis in 10-week-old NOD and NOD/CRIg KO mice. Hematoxylin and eosin staining of pancreatic paraffin sections. Arrowheads depict massive immune infiltration. Bar, 50 um. (**C**) Flow cytometric analyses of digested pancreases of NOD/CRIg KO mice and littermate controls (n = 7 in each group). (Left) The percentages of pancreatic Treg cells in age-matched NOD and NOD/CRIg KO mice (mixed of both females and males). (Right) The ratio between Treg cells and CD8^+^ T cells (n = 7 in each group). (**D**) The production of IFN-γ in CD4^+^ Tconv and CD8^+^ T cells. Pancreatic digestions were the same as in (**C**). Data are representative of three (**A, B**) or four (**C, D**) experiments. Student's *t*-test was used. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001.](elife-29540-fig1){#fig1}

We next asked whether CRIg deficiency in TRMs was correlated with altered compositions and activities of islet T cells. Due to the heterogeneities of insulitis in NOD mice, we calculated the ratios between regulatory and pathogenic cells in pancreatic islets to more accurately reflect how CRIg deficiency affected the severity of insulitis within each individual mouse. Comparing to age-matched wildtype NOD mice, CRIg knockout (KO) mice exhibited an altered balance between regulatory and effector T cells, reflected by: (i) The fraction of Treg cells was reduced in pancreatic islets ([Figure 1C](#fig1){ref-type="fig"}). Such a reduction of Treg abundance was not seen in lymphoid organs ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}), supporting a tissue-specific immunoregulatory role of CRIg. (ii) The ratio between pancreatic Treg and CD8^+^ T cells was also reduced in NOD/CRIg KO mice ([Figure 1C](#fig1){ref-type="fig"}). We next analyzed cytokine production in T cells isolated from NOD/CRIg KO and littermate control mice. Both CD4^+^ and CD8^+^ T cells isolated from the pancreatic islets, not lymphoid organs, of NOD/CRIg KO mice exhibited significantly increased production of IFN-γ ([Figure 1D](#fig1){ref-type="fig"}), which is a key pathogenic cytokine in T1D development ([@bib18]). We next examined whether CRIg^+^ TRMs interacted with T cells. Immunostaining of pre-diabetic islets (with ongoing insulitis) from NOD mice showed that there were cell clusters containing both CRIg^+^ TRMs and T cells in close proximity, suggesting a cell-cell contact between CRIg^+^ TRMs and T cells ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}).

In summary, pancreatic CRIg^+^ TRMs form a protective barrier surrounding the islets to prevent insulitis and impact local immuno-balance between effector and regulatory T cells. CRIg molecule plays a central role for these TRMs to exert their diabetes-suppressing effect.

CRIg suppresses T cell proliferation by attenuating early T cell activation signaling {#s2-2}
-------------------------------------------------------------------------------------

CRIg has been reported to suppress T cell activation and cytokine production ([@bib58]; [@bib22]). However, how CRIg regulates T cell activities remains unknown. Consistent with previous reports ([@bib58]; [@bib22]), we found that plate-coated CRIg-Ig, not control Ig, suppressed T cell proliferation in vitro ([Figure 2A](#fig2){ref-type="fig"}). We asked whether CRIg affected early activation phase, or late proliferation phase, of T cells. To answer this question, we isolated CD4^+^ CD25^-^ conventional T (Tconv) cells and cultured them in vitro for 3 days with anti-CD3/CD28. These cultured T cells were supplemented with plate-coated CRIg-Ig under two different conditions - either only the first 24 hours (hr), or only the late 48 hr, of the in vitro culture. We found that the presence of CRIg-Ig during the first 24 hr was sufficient to suppress T cell proliferation, to an extent similar to the condition where CRIg-Ig was present all time of the culture ([Figure 2A](#fig2){ref-type="fig"}). In contrast, when CRIg-Ig was only present during the last 48 hr, its suppressive effect on T cell proliferation was largely abolished ([Figure 2A](#fig2){ref-type="fig"}). Therefore, CRIg interferes early T cell activation. This notion was further supported by flow cytometric analysis of the expression of CD69 and CD25, two cell-surface markers depicting T cell activation. In a time-course assay, the majority of T cells exhibited an upregulation of both CD69 and CD25 within 17 hr. CRIg-Ig potently suppressed the upregulation of both CD69 and CD25 in T cells ([Figure 2B](#fig2){ref-type="fig"}). We then examined whether CRIg affected TCR signaling pathways. Using phosphorylation assays, we found that the presence of plate-bound CRIg-Ig suppressed the phosphorylation of ZAP70, ERK1/2, AKT and ribosomal protein S6 ([Figure 2C](#fig2){ref-type="fig"}). These data suggest that CRIg-Ig dampens several pathways that are crucial for early T cell activation, including the most proximal signaling complex (ZAP70), the ERK-MAPK pathway (ERK1/2, and S6) and the AKT-MTOR pathway (AKT, S6).

![CRIg suppresses T cell activation.\
(**A**) CFSE-labeled CD4^+^ CD25^-^ Tconv cells were stimulated with anti-CD3/CD28. Plate-bound CRIg-Ig, or control Ig, was added either all time during T cell culture (3 d), or only the first 24 hr, or the late 48 hr. T cell proliferation was measured by CFSE dilution. (**B**) The expression of early T cell activation markers-CD69 and CD25 in cultured Tconv cells with plate-bound control Ig, or CRIg-Ig. (**C**) The phosphorylation of early T cell activation cascade proteins. CD4^+^ CD25^-^ Tconv cells were activated in vitro with anti-CD3/CD28 in the presence of plate-bound control Ig, or CRIg-Ig. (**D**) The binding of CRIg to activated T cells. CD4^+^ CD25^-^ Tconv cells were activated in vitro by anti-CD3/CD28 for various lengths of time (12 hr, 24 hr and 72 hr). At each time-point of T cell activation, various concentrations of biotinylated control Ig or CRIg-Ig were incubated with T cells at 37^°^C for 1 hr. The binding of biotin-labeled Ig proteins was detected using streptavidin-conjugated antibody. (left) Representative histograms of SA-PercpCy5.5 MFIs depicting the binding intensities of biotinylated proteins (25 ug/ml) bound to T cells. (right) Statistical data showing fold-changes of SA-PercpCy5.5 MFIs between CRIg-Ig and control Ig at each time-point and each concentration. *P* values were calculated by comparing the binding intensities between biotin-CRIg-Ig and biotin-control-Ig. The data are representative from five (**A**), three (**B**), and four (**C, D**) experiments. Student's *t*-test was used. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001, n.s., non-significant.](elife-29540-fig2){#fig2}

CRIg has also been reported as a complement receptor that binds to C3b, iC3b and C3c ([@bib32]). We asked whether complement components were involved in CRIg elicited T cell suppression. Using a specific monoclonal antibody (mAb) (clone 14G8) (ref. \[[@bib26]\]) that can block the binding of CRIg to C3 components, we found that 14G8 did not abolish T cell suppression by CRIg, suggesting that complements were not involved in CRIg-mediated T cell suppression ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). This notion was further supported by that CRIg can attenuate TCR activation in serum-free condition, which was deprived of complements ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). In fact, CRIg-Ig mediated suppression of T cell proliferation was even enhanced by anti-CRIg (e.g., clone 14G8) ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}), or other clonotypes of anti-CRIg mAbs that do not interfere the binding of CRIg to C3 components (data not shown), suggesting a possible cross-linking effect by anti-CRIg mAbs on CRIg-Ig. In line with this, we found that soluble CRIg-Ig did not suppress T cell proliferation. In contrast, pre-coating the plates with anti-CRIg mAb (clone 14G8, or 17C9) enabled soluble CRIg-Ig to potently suppress T cell proliferation ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}).

We then asked whether CRIg can directly bind to T cells. In this regard, isolated CD4^+^ Tconv cells were activated in vitro with anti-CD3/CD28 and cultured for various lengths of time (12, 24, and 72 hr, respectively). At each stage of T cell activation, these cells were incubated with biotinylated CRIg-Ig or control Ig at 37°C for 1 hr, and the binding was measured using a streptavidin-conjugated secondary Ab. We found that CRIg can bind to activated T cells, in a dose-dependent manner ([Figure 2D](#fig2){ref-type="fig"}). Interestingly, we observed stronger binding of CRIg-Ig to T cells at their early, not late, stage of in vitro activation (12 hr and 24 hr versus 72 hr) ([Figure 2D](#fig2){ref-type="fig"}). This was consistent with the suppressive effect of CRIg-Ig on T cells ([Figure 2A](#fig2){ref-type="fig"}). CRIg-Ig can also bind to activated Treg cells. However, in any analyzed concentration of CRIg-Ig, or time-point, the binding intensity was lower comparing to that for Tconv cells ([Figure 2---figure supplement 3A](#fig2s3){ref-type="fig"}). Consistent with this, Treg cells were less sensitive to CRIg-mediated suppression ([Figure 2---figure supplement 3B](#fig2s3){ref-type="fig"}).

The extracellular domains of CRIg contain one IgV-type of immunoglobulin ([@bib32]; [@bib58]). Without knowing the cognate receptor(s) for CRIg, we tested whether CRIg could bind to any known coinhibitory molecules of immunoglobulin family. In a competition assay, CD4^+^ Tconv cells were activated with anti-CD3/CD28 in the presence of plate-bound CRIg-Ig, or control Ig. Based on the availabilities of Ig fusion proteins, we tested CTLA-4, PD-1, VISTA, CD226 and TIGIT to assess whether the soluble forms of any of these proteins can block the effect of CRIg-Ig on T cell proliferation. None of these tested soluble proteins exhibited a blocking effect ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}).

In summary, CRIg preferentially suppresses effector T cells via binding to a putative receptor in these cells at their early stage of activation and attenuating early TCR activation signaling.

CRIg enhances iTreg differentiation in vitro and regulates pTreg development at tissue sites {#s2-3}
--------------------------------------------------------------------------------------------

B7/CD28 family coinhibitory molecules (e.g., PD-L1) have been reported to promote Treg differentiation ([@bib20]; [@bib59]; [@bib1]). We asked whether CRIg has a similar effect on Treg differentiation. We assessed this possibility in an in vitro TGF-β - induced Treg (iTreg) condition ([@bib11]). Purified CD4^+^ Foxp3(GFP)^-^ Tconv cells from the spleen and LNs of NOD/Foxp3^GFP^ mice ([@bib28]) were cultured in the presence of anti-CD3/CD28, IL-2 and TGF-β to induce iTreg differentiation. As expected, TGF-β promoted iTreg differentiation in a dose-dependent manner. At any given dose of TGF-β, CRIg-Ig further enhanced the generation of iTreg cells ([Figure 3A](#fig3){ref-type="fig"}). CRIg-mediated enhancement of iTreg generation was more profound when TGF-β concentration was relatively low (e.g., there was a more than two-fold increase of iTreg induction by CRIg-Ig with 0.2 ng/ml TGF-β) ([Figure 3A](#fig3){ref-type="fig"}). To assess whether CRIg-Ig alone could induce the conversion of Tconv cells into iTreg cells, an anti-TGF-β neutralizing mAb (clone 1D11) (ref. \[[@bib8]\]) was added to eliminate any trace-amount of TGF-β in the culture medium. In the absence of TGF-β, CRIg-Ig alone did not induce the generation of iTreg cells ([Figure 3B](#fig3){ref-type="fig"}). Treg cells can be converted from Tconv cells under the conditions where antigens (Ag) are encountered in the absence of optimal costimulation ([@bib37]; [@bib57]). To examine whether CRIg has an effect on Ag-induced Treg generation, we cultured total splenocytes from NOD/BDC2.5 mice with the cognate Ag mimotopes ([@bib30]; [@bib36]). Compared with control Ig, CRIg-Ig induced a 2-fold increase of Treg generation ([Figure 3C](#fig3){ref-type="fig"}), suggesting a role of CRIg in promoting Ag-stimulated Treg generation. We next evaluated whether CRIg^+^ macrophages can promote iTreg generation. Using an in vitro Ag-stimulated iTreg generation condition, we found that even though CRIg^-^ macrophages can modestly promote Ag-induced iTreg generation, this effect was significantly elevated by CRIg^+^ macrophages ([Figure 3D](#fig3){ref-type="fig"}). Therefore, CRIg promotes iTreg generation induced by either TGF-β, or Ag.

![CRIg promotes iTreg generation in vitro.\
(**A**) (left) Representative FACS plots depicting the generation of iTreg cells in the presence of CRIg-Ig, or control Ig, under various concentrations of TGF-β. (right) Statistics of multiple experiments. (**B**) Tconv cells were cultured in the condition of anti-CD3/CD28 and IL-2, anti-TGF-β neutralizing antibody (clone 1D11) and either control Ig, or CRIg-Ig. (**C**) Total splenocytes from 8-week-old NOD/BDC2.5/Thy1.1 mice were labeled with CTV and cultured with BDC2.5 mimotope (100 ng/ml) for 3 days. The generation of Treg cells were analyzed by intracellular Foxp3 staining. (**D**) iTreg generation in vitro as in (C) with the inclusion of CRIg^+^ or CRIg^-^ macrophages, sorted from peritoneal cavity. (**E**) Purified CD4^+^Foxp3 (GFP)^-^ T cells from NOD/BDC2.5/Foxp3^GFP^/Thy1.1 mice were transferred into 4-week-old NOD mice, followed by *i.p*. injection of CRIg-Ig, or control Ig every other day for 2 weeks. (**F**) Purified CD4^+^Foxp3 (GFP)^-^ T cells from NOD/BDC2.5/Foxp3^GFP^/Th1.1 mice were transferred into 4-week-old NOD or NOD/CRIg KO mice. The generation of Foxp3(GFP)^+^ cells in pancreatic islets, panLNs and inguinal LNs(ILNs) was analyzed 2 weeks after the transfer. (**G**) Flow cytometric analyses of Helios^- ^Treg cells from pancreas, colon and lung of NOD/CRIgKO and wildtype controls. (**H, I**) Purified CD4^+^ Foxp3(GFP)^-^ T cells were cultured with either control Ig or CRIg-Ig for 18 hr and analyzed for the phosphorylation of AKT (**H**) and ribosomal protein S6 (**I**). Dotted line, control Ig; solid line, CRIg-Ig. Data are representative of five (**A**), three (**B--I**) experiments. Student's *t*-test was used. n.s., non-significant. \*p\<0.05; \*\*\*p\<0.001; \*\*\*\*p\<0.0001. Ctl, control; KO, CRIg knockout.](elife-29540-fig3){#fig3}

To evaluate the in vivo effect of CRIg in peripherally Treg (pTreg) generation, we transferred highly purified CD4^+ ^Foxp3(GFP)^-^ Tconv cells isolated from NOD/BDC2.5/Thy1.1^+^/Foxp3^GFP^ mice into 4-week-old NOD mice. We found that a 2-week in vivo CRIg-Ig treatment preferentially enhanced pTreg development in pancreatic islets, not pancreas- draining or non-draining lymph nodes ([Figure 3E](#fig3){ref-type="fig"}). Conversely, we transferred purified BDC2.5^+^ CD4^+^ Foxp3(GFP)^-^ Tconv cells into either NOD or NOD/CRIg KO mice. The generation of Treg cells was compromised in the absence of CRIg ([Figure 3F](#fig3){ref-type="fig"}). Of note, this reduction only occurred in the pancreas, not in pancreas-draining or non-draining lymph nodes, suggesting a local microenvironment-specific role of CRIg in regulating pTreg generation. Consistent with the role of CRIg in affecting Treg cells at tissue sites, we found that Helios^-^ peripherally-induced Treg (pTreg) ([@bib50]) cells were preferentially reduced in pancreas and colon of NOD/CRIg KO mice, compared with wildtype controls ([Figure 3G](#fig3){ref-type="fig"}). In contrast, since there was no CRIg expression in lung macrophages ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}), pTreg cells in the lung were not affected by CRIg deficiency.

We next investigated what pathways were affected in CRIg-promoted iTreg cells. It has been demonstrated that mTOR pathway kinase AKT has a negative impact on Treg cell development ([@bib31]). We asked whether CRIg affected AKT activity during iTreg differentiation. Under iTreg induction condition, plate-bound CRIg-Ig more potently suppressed the phosphorylation of AKT ([Figure 3H](#fig3){ref-type="fig"}). Similarly, the phosphorylation of S6 ribosomal protein, a downstream target of mTOR pathway was also more significantly suppressed by CRIg-Ig ([Figure 3I](#fig3){ref-type="fig"}). However, CRIg-Ig did not enhance TGF-β induced phosphorylation of Smad2/3 ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Thus, CRIg-Ig potentiates iTreg generation via suppressing AKT-MTOR pathway.

CRIg stabilizes Foxp3 expression in iTreg cells {#s2-4}
-----------------------------------------------

iTreg cells lose their expression of Foxp3 when they are restimulated with TCR signaling ([@bib17]; [@bib63]). We asked whether CRIg-Ig affected the stability of iTreg cells. CD4^+ ^Foxp3(GFP)^-^ cells from NOD/Foxp3^GFP^ mice were FACS purified and cultured under the iTreg differentiation condition. After 24 hr, about 20% of cultured cells were Foxp3(GFP)^+^. We sorted these GFP^+^ cells and recultured them with anti-CD3/CD28 and IL-2, in the presence of either CRIg-Ig, or control Ig ([Figure 4A](#fig4){ref-type="fig"}). An anti-TGF-β neutralizing antibody (clone 1D11) was added to eliminate the trace amount of TGF-β in the culture medium. After 3 days, about 50% of control iTreg cells lost their expression of Foxp3 ([Figure 4B](#fig4){ref-type="fig"}). In contrast, in the presence of plate-bound CRIg-Ig, a significantly higher fraction of iTreg cells retained Foxp3 ([Figure 4B](#fig4){ref-type="fig"}). The loss of Foxp3 in restimulated iTreg cells was exacerbated over the course of cell dividing. This instability of Foxp3 expression was repressed by CRIg-Ig, especially when the cells underwent multiple divisions ([Figure 4C](#fig4){ref-type="fig"}). Moreover, the expression level of Foxp3 protein on a per cell basis was also higher in restimulated iTreg cells in the presence of CRIg-Ig, compared to that in control group ([Figure 4D](#fig4){ref-type="fig"}). Notably, this Treg-stabilizing effect of CRIg is TGF-β independent, because we have added an anti-TGF-β neutralizing mAb to eliminate any trace amount of TGF-β. Thus, CRIg retains the expression of Foxp3 in Treg cells. In line with a Treg--stabilizing effect, CRIg preconditioned iTreg cells exhibited an enhanced suppressive capacity in an in vitro Treg suppression assay ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}).

![CRIg stabilizes Foxp3 expression in TGF−β induced iTreg cells.\
(**A**) Experimental setting. (**B**) The fraction of Foxp3 positivity and the division of recultured iTreg cells. Left, representative FACS plots; right, the statistics of multiple experiments (n = 7). (**C**) The percentage of cells retaining Foxp3 expression in each cell division. (**D**) The MFI of Foxp3 protein in each generation of cell division. (**E**) The methylation percentage at each CpG motif in *Foxp3* CNS2 of control iTreg (grey bars), or CRIg iTreg cells (black bars) (see [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}) (**F**) In vitro differentiated iTreg cells were restimulated with anti-CD3/CD28, and various concentrations of IL-2, in the presence of CRIg-Ig, or control Ig. The fraction of cells retaining Foxp3 expression was analyzed after 3 days. (**G**) The expression of IL-2Rβ in control and CRIg iTreg cells after 3 days of culture. (**H**) The phosphorylation of STAT5 in control and CRIg iTreg cells. Data are representative of seven (**B--D**), two (**E**), and three (**F--H**) experiments, respectively. Student's t-test was used. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001.\
10.7554/eLife.29540.016Figure 4---source data 1.The methylation percentage at each CpG motif in *Foxp3* CNS2 of control iTreg cells, CRIg iTreg cells and ex vivo Treg cells (associated with [Figure 4E](#fig4){ref-type="fig"}).](elife-29540-fig4){#fig4}

CRIg-Ig stabilizes iTreg cells by enhancing their responsiveness to IL-2 {#s2-5}
------------------------------------------------------------------------

We next attempted to identify the mechanisms by which CRIg stabilized Foxp3 in Treg cells. Demethylation of CpG sites in the second CNS region (CNS2) of *Foxp3* is critical for Treg stability ([@bib19]; [@bib64]). We asked whether CRIg-Ig had an effect on *Foxp3* CpG demethylation. We used bisulfite colony sequencing of PCR products of CNS2 regions ([@bib35]). To this end, iTreg cells were generated, sorted as GFP(Foxp3)^+^ cells and recultured with anti-CD3/CD28 and IL-2, in the presence of CRIg-Ig, or control Ig. After 3 days, genomic DNAs from re-sorted GFP^+^ cells were extracted and processed for bisulfite sequencing of the *Foxp3* CNS2 region. As expected, CpG sites in *Foxp3* CNS2 region of control iTreg cells were highly methylated ([Figure 4E](#fig4){ref-type="fig"}). A similar profile of CpG methylation was observed in CRIg iTreg cells ([Figure 4E](#fig4){ref-type="fig"}). These data suggest that CRIg-promoted iTreg stability is not a consequence of demethylation in *Foxp3* CNS2 region.

IL-2 signaling is critical for Treg stability, by retaining the expression of Foxp3 (refs \[[@bib14]; [@bib10]\]). We asked whether iTreg cells, when restimulated in the presence of CRIg-Ig, were more responsive to limited amount of IL-2. In this regard, TGF-β induced iTreg cells were sorted and restimulated with anti-CD3/CD28, in the presence of CRIg-Ig or control Ig, with various doses of IL-2. In control iTreg cells restimulated with anti-CD3/CD28, increased concentrations of IL-2 did not prevent the loss of Foxp3 in these cells. In contrast, the presence of CRIg-Ig resulted in a significantly higher fraction of restimulated iTreg cells retaining their expression of Foxp3, in the presence of IL-2 ([Figure 4F](#fig4){ref-type="fig"}). CRIg induced iTreg cells expressed a higher level of IL-2Rβ ([Figure 4G](#fig4){ref-type="fig"}), suggesting an enhanced responsiveness of these cells to IL-2. Signal transducer and activator of transcription 5 (STAT5) is key downstream target of IL-2 signaling ([@bib7]; [@bib62]). IL-2-induced STAT5 phosphorylation in iTreg cells was significantly enhanced by CRIg-Ig ([Figure 4H](#fig4){ref-type="fig"}). Therefore, CRIg retains Foxp3 expression in iTreg cells by enhancing their responsiveness to IL-2.

CRIg stabilizes Treg cells in vivo in lymphopenic condition {#s2-6}
-----------------------------------------------------------

Treg cells lose Foxp3 expression when they are transferred into lymphopenic mice ([@bib15]; [@bib4]). Using neonatal NOD mice as lymphopenic hosts, we analyzed whether CRIg-preconditioned iTreg cells were more stable in vivo. CD4^+ ^Foxp3(GFP)^-^ cells from NOD/Foxp3^GFP^/Thy1.1^+^ mice, or NOD/Foxp3^GFP^/Thy1.1^+ ^Thy1.2^+^ mice were sorted and differentiated into iTreg cells by either TGF-β (control iTreg), or TGF-β plus CRIg-Ig (CRIg iTreg). Both control iTreg cells and CRIg iTreg cells were sorted as GFP^+^ cells and mixed at 1:1 ratio before transferring into neonatal NOD mice (Thy1.2^+^) ([Figure 5A](#fig5){ref-type="fig"}). One week later, transferred iTreg cells from both spleen and pancreatic islets were analyzed. Control and CRIg iTreg cells exhibited similar degrees of engraftments ([Figure 5B,C](#fig5){ref-type="fig"}), suggesting that preconditioning with CRIg did not affect homeostatic survival and expansion of these adoptively transferred cells. However, iTreg cells generated in the presence of CRIg-Ig showed an enhanced stability under lymphopenic condition. In spleen, a significantly higher fraction of transferred CRIg-iTreg cells maintained their expression of Foxp3 ([Figure 5B](#fig5){ref-type="fig"}). Although CRIg (plate-bound) was present during the in vitro generation of iTreg cells, it was dissociated from these cells after adoptive transfer. Since there was no CRIg expression in spleen ([@bib32]; [@bib58]) (and our unpublished data), it thus suggests that a continuous cell-cell contact between Treg cells and CRIg^+^ TRMs is not necessarily needed for retaining Foxp3 expression. The instability of adoptively transferred iTreg cells was more profoundly exacerbated in pancreatic islets, as expected. However, preconditioning with CRIg before the adoptive transfer retained a significantly higher percentage of Foxp3 expression ([Figure 5C](#fig5){ref-type="fig"}). Thus, iTreg cells generated by TGF-β plus CRIg-Ig are more stable in vivo.

![CRIg stabilizes adoptively transferred iTreg cells in vivo.\
(**A**) Experimental design. (**B, C**) One week later, the transferred cells were isolated from spleen (**B**) and pancreatic islets (**C**) and were analyzed for the expression of Foxp3. Control iTreg cells, Thy1.1^+ ^Thy1.2^+^; CRIg iTreg cells, Thy1.1^+ ^Thy1.2^-^. Data are representative of two independent experiments with 9 mice in total. Student's t-test was used. \*\*\*p\<0.001.](elife-29540-fig5){#fig5}

In vivo CRIg modulation corrects immune dysregulation in an autoimmune condition {#s2-7}
--------------------------------------------------------------------------------

Immune dysregulation characterized by loss-of balance between regulatory and effector immune cells is key for the pathogenesis of many autoimmune diseases, including T1D ([@bib6]; [@bib2]). Our data suggested that CRIg may possess a role in modulating the dysregulated immune responses. We assessed this possibility in NOD mice, the primary animal models for human T1D ([@bib2]). Our in vitro studies revealed that cross-linking CRIg with an anti-CRIg mAb (e.g., clone 17C9) significantly enhanced TGF-β-induced iTreg generation ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). In vivo analyses revealed that serum half-life of CRIg-Ig was significantly prolonged when an anti-CRIg mAb (clone 17C9) was administrated simultaneously with CRIg-Ig ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). Moreover, anti-CRIg mAb alone did not alter the compositions of T cells in vivo, including Treg cells ([Figure 6---figure supplement 3A](#fig6s3){ref-type="fig"}). Therefore, we used CRIg-Ig/anti-CRIg mAb complex to treat NOD mice. Ten-week old pre-diabetic NOD mice were treated with CRIg-Ig/anti-CRIg complex or control Ig for two weeks. Immune cells isolated from the spleen, pancreatic draining lymph nodes (panLNs) and pancreatic islets were analyzed. We first focused on analyzing whether in vivo CRIg modulation altered the balance between regulatory and effector T cells in NOD mice. Of note, the ratios between Treg cells and CD4^+^ Tconv cells in pancreatic islets were significantly increased in CRIg-Ig/anti-CRIg complex treated mice, with about 50% of the mice exhibited a robust response ([Figure 6A](#fig6){ref-type="fig"}). Similar results were observed in the ratios between Treg and CD8^+^ T cells ([Figure 6A](#fig6){ref-type="fig"}). Of note, such an effect was only seen at tissue sites (pancreatic islets), not in lymphoid organs, such as panLNs ([Figure 6B](#fig6){ref-type="fig"}), or spleen ([Figure 6---figure supplement 3B](#fig6s3){ref-type="fig"}). Thus, in vivo CRIg modulation rebalances immune compositions in situ under an autoimmune condition.

![CRIg restores immune tolerance in pancreatic islets of NOD mice.\
The ratios of Treg/Tconv cells, and Treg/CD8^+^ T cells in the pancreas (**A**) and panLNs (**B**) of control (n = 14) and CRIg-Ig/anti-CRIg treated mice (n = 16). The expression of Helios (**C**) and ICOS (**D**) in Treg cells from pancreatic islets of control (n = 7 in C, n=3 in D) and CRIg-Ig/anti-CRIg (labeled as CRIg/mAb in the figure panels, n = 8 in C, n=4 in D) treated mice. The production of IFN-γ (**E**) and IL-17 (**F**) in CD4^+^ Tconv cells from pancreatic islets in control Ig (n = 5) and CRIg-Ig/anti-CRIg (n = 6) treated mice. Data are representative of six (**A, B**), three (**C**), and two (**D--F**) experiments, respectively. Student's t-test was used. n.s., non-significant; \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001.](elife-29540-fig6){#fig6}

In addition to altering the ratios between regulatory and effector T cells, we asked whether CRIg affected the functional properties of T cells. Interestingly, in vivo CRIg modulation increased the proportion of Helios^-^ Treg cells ([Figure 6C](#fig6){ref-type="fig"}), indicating an enhanced generation of pTreg cells ([@bib55]). This is consistent with the results of CRIg-Ig promoted in vivo pTreg generation from adoptively transferred Tconv cells ([Figure 3E](#fig3){ref-type="fig"}). Elevated expression of ICOS is a marker for effector Treg cells ([@bib51]). We found that a significantly increased proportion of islet Treg cells from CRIg-Ig/anti-CRIg treated mice were ICOS^hi^ ([Figure 6D](#fig6){ref-type="fig"}). Thus, in vivo CRIg modulation increases pTreg development and functional maturation at tissue sites.

As a consequence of CRIg on helper T (Th) cell differentiation, we observed a significantly reduced IFN-γ production in CD4^+^ Tconv cells from pancreatic islets ([Figure 6E](#fig6){ref-type="fig"}). However unexpectedly, IL-17^+^ T (Th17) cell differentiation was significantly increased in pancreatic islets of CRIg-Ig/anti-CRIg complex treated mice ([Figure 6F](#fig6){ref-type="fig"}). The role for Th17 cells in T1D has been controversial, either diabetogenic ([@bib16]; [@bib23]) or protective ([@bib56]; [@bib43]). One model of Th17's role in T1D is that these cells convert to diabetogenic IFN-γ^+^ Th1 cells in vivo ([@bib41]; [@bib5]). Because we have previously found that the onset of diabetes was suppressed in CRIg-Ig treated NOD mice ([@bib22]), it thus can be speculated that these accumulated Th17 cells in pancreatic islets are not diabetogenic. The elevated proportion of IL-17^+^ T cells in pancreatic islets of CRIg-treated NOD mice may be due to a blocked conversion from Th17 into Th1 cells.

Thus, in vivo CRIg modulation corrects immune dysregulation occurred in autoimmune conditions. Such an outcome is achieved through a dual effect of CRIg: the suppression of pathogenic Th1 cells and the promotion of Treg cell differentiation and function. The diabetogenicity of effector T cells can be further dampened by elevated Treg abundance and function. Overall, CRIg-mediated immunomodulation diverts autoimmunity towards immunological tolerance.

The expression of CRIg in TRMs is influenced postnatally by microbial signals {#s2-8}
-----------------------------------------------------------------------------

The above findings support a role of CRIg as a tissue environment-specific checkpoint molecule for immunological homeostasis. The dearth of CRIg expression in TRMs is tightly correlated with exacerbated tissue inflammation ([Figure 1](#fig1){ref-type="fig"}). Therefore, it is worth investigating what factors and signals regulate the expression of CRIg in TRMs. CRIg is abundantly expressed in a number of organs/tissues, including liver Kupffer cells of adult mice ([Figure 7A](#fig7){ref-type="fig"}) ([@bib32]). However, in contrast, CRIg was almost completely absent in the liver from neonatal (day one post birth) mice, though F4/80^+^ Kupffer cells were readily detected ([Figure 7A](#fig7){ref-type="fig"}). We confirmed the absence of CRIg expression in macrophages from other tissues, including the pancreas in neonatal mice ([Figure 7B](#fig7){ref-type="fig"}). Therefore, CRIg is not constitutively expressed in macrophages, rather, is contingent upon extrinsic signals arisen postnatally. We then asked when the expression of CRIg was induced postnatally. For this, we tracked the expression of CRIg in peritoneal large TRMs (F4/80^hi^) longitudinally in both NOD and B6 strains ([Figure 7C](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). Clearly, there was a sharp increase of CRIg expression in macrophages around the time of weaning, a time-point when mice were exposed to environmental cues ([@bib39]). The colonization of gut microbiota at early age, especially around the time of weaning is critical for the postnatal development of immune system. To evaluate whether the expression of CRIg was influenced by gut microbiota, we treated adult B6 mice with a combination of four antibiotics (vancomycin, metronidazole, neomycin and ampicillin, *VMNA*) ([@bib48]) for one week in drinking water. We analyzed the expression of CRIg in various tissues, including pancreas, colon and peritoneal cavity. Though the fraction of CRIg^+^ TRMs in peritoneal cavity was not affected by antibiotic treatment, in contrast, at tissue sites (colon and pancreas), the fractions of CRIg^+^ TRMs were significantly decreased ([Figure 7D--F](#fig7){ref-type="fig"}). Of note, at all examined locations, antibiotic treatment significantly diminished CRIg expression on a per cell basis in macrophages ([Figure 7D--F](#fig7){ref-type="fig"}). These data suggest that CRIg expression in TRMs is induced postnatally by microbial signals.

![The expression of CRIg in TRMs is influenced by environmental factors.\
(**A**) The expression of CRIg in liver Kupffer cells of adult (7 weeks of age) and neonatal (day one post birth) B6 mice. Green, F4/80; Red, CRIg. (**B**) The expression of CRIg in pancreatic islets of adult (10 weeks of age) and neonatal (day seven post birth) NOD mice. Green, F4/80; Red, CRIg. (**C**) Longitudinal analysis of CRIg expression in peritoneal F4/80^hi^ TRMs of NOD mice. Red: females; Blue, males. Dotted green line depicts the time of weaning. (**D--F**) The percentages and the MFI of CRIg expression in TRMs from peritoneal cavity (**D**), pancreatic islets (**E**) and colon (**F**) of control and antibiotics treated B6 mice, respectively. (**G**) The expression of retinoic acid receptors in CRIg^+^ and CRIg^-^ TRMs isolated from peritoneal cavity of 7 weeks old B6 mice. (**H**) CRIg^+^ macrophages were isolated from peritoneal cavity and cultured in vitro in the presence or absence of ATRA. The expression of CRIg in cultured cells were analyzed 3 days later. blue line, no ATRA; red line, with ATRA. (**I, J**) In vivo treatment of 7 weeks old B6 mice with an inverse pan-RA agonist BMS 493 to block RA signaling. The expression of CRIg in TRMs from peritoneal cavity (**I**) and pancreatic islets (**J**) was analyzed 3 days later. Data are representative of three (**A, B, D--J**), and more than five (**C**) experiments, respectively. Student's t-test was used. n.s., non-significant; \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001; \*\*\*\*p\<0.0001. w/o, without.](elife-29540-fig7){#fig7}

Retinoic acid signaling retains CRIg expression in macrophages in vitro and in vivo. {#s2-9}
------------------------------------------------------------------------------------

We have found that TRMs (both CRIg^+^ and CRIg^-^ subsets) abundantly express retinoic acid (RA) receptors (RAR) ([Figure 7G](#fig7){ref-type="fig"}), suggesting that these cells are able to respond to RA. Therefore, we tested whether RA affected CRIg expression. We isolated CRIg^+^ macrophages from peritoneal cavity of 7-week-old B6 mice and cultured them in the presence, or absence of *all-trans* RA (ATRA), the active form of RA. In the absence of ATRA, the expression of CRIg decreased (reflected by a lower MFI of CRIg) after 3-day culture. In contrast, ATRA retained the expression of CRIg, to a level comparable to that in freshly isolated CRIg^+^ macrophages ([Figure 7H](#fig7){ref-type="fig"}). Interestingly, ATRA also increased CRIg expression in isolated CRIg^-^ macrophages ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}), suggesting that RA signaling may be involved in inducing CRIg expression in macrophages. *Might RA affect CRIg expression* in vivo? To test this, we treated 7-week-old B6 mice with an inverse pan-RA agonist BMS 493 (ref \[[@bib9]\]) to block RA signaling. Compared with control vehicle-treated mice, BMS 493 significantly reduced CRIg expression in peritoneal, but not pancreatic F4/80^hi^ TRMs ([Figure 7I,J](#fig7){ref-type="fig"}). Consistently, BMS 493 treatment also reduced the expression of CRIg in peritoneal macrophages in an adoptive transfer setting, where donor CRIg^+^ macrophages were purified from congenically-labeled mice ([Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}). Collectively, these data suggest that RA signaling is involved in regulating CRIg expression in TRMs in a tissue-specific manner.

Discussion {#s3}
==========

How adaptive immunity at tissue sites is regulated by local microenvironment remains poorly understood. We here define a new model of regulating T cell activities by tissue resident cells. In this model, TRMs sense environmental cues and express CRIg. Through the function of CRIg, tissue-specific autoimmunity is suppressed and immune tolerance is reinforced. Multiple mechanisms are involved in this model to promote immune tolerance. First, CRIg^+^ TRMs form a barrier protecting pancreatic islets from succumbing to destructive insulitis. Second, CRIg preferentially suppresses effector T cell proliferation. Third, CRIg promotes the differentiation and stability of Treg cells.

CRIg^+^ TRM mediated protection provides one explanation why not all islets are equally destructed during T1D development. In animal models and arguably in human patients of T1D, islet autoimmunity (insulitis) is universally present. However, not all insulitis proceeds to become diabetic ([@bib22]; [@bib3]; [@bib46]). Even in genetically identical monozygotic twins, the concordance of T1D incidence is only about 40--50%. It is still elusive what determines the risk of one individual to become diabetic. Moreover, not all islets are equally destroyed and there exist intact islets even in longstanding diabetic patients ([@bib6]). It is unclear why some islets are free from immune infiltration while the others are not. CRIg^+^ TRMs specifically localize in the capsular area of an islet. The dearth of CRIg expression in these TRMs is correlated with the aggressiveness of insulitis in each individual islet. In line with this, insulitis is markedly exacerbated in NOD mice with CRIg-null mutation.

Several aspects of T cell activities can be modulated by CRIg. For each of them, our data also provide critical mechanistic insights. First, CRIg suppresses T cell proliferation by attenuating the activation of multiple TCR signaling cascades, including the most proximal signaling complex, the ERK-MAPK pathway and the AKT-MTOR pathway. The preferential suppression of effector T cells by CRIg is likely due to a higher level of the expression of a putative CRIg receptor in effector T cells than that in Treg cells. Our binding assays suggest that the receptor for CRIg is only transiently induced during early activation phase in T cells. Using competition assays, we have excluded a number of known coinhibitory molecules of immunoglobulin family as a potential receptor for CRIg. Other approaches including biochemical assays and protein interaction arrays will be employed to identify the receptor for CRIg. Second, reminiscent of the role of PD-L1 (refs \[[@bib20]; [@bib59]\]), CRIg can also promote TGF-β induced Treg differentiation. CRIg does not directly enhance TGF-β signaling, instead, it robustly suppresses AKT signaling under iTreg induction condition, thus potentiating the differentiation of iTreg cells. Beyond promoting iTreg differentiation, another key finding is that CRIg increases the stability of Treg cells. This Treg-stabilizing effect of CRIg is not attributed to epigenetic modification of *Foxp3* promoter, instead, CRIg makes Treg cells more sensitive to IL-2 by increasing the expression of IL-2Rβ and the phosphorylation of STAT5. Moreover, our data suggest that Treg cells do not need continuous cell-cell contact with CRIg^+^ TRMs to maintain Foxp3 expression.

Adoptive transfer of Treg cells is a promising strategy to induce immune tolerance in the treatment of human autoimmune diseases and organ transplantations ([@bib53]). However, variable stabilities of in vitro generated iTreg cells hinder this therapeutic option. We propose that CRIg may become a potential candidate to overcome the barrier of instability in Treg-based therapies. Correlated with the enhanced stability of CRIg iTreg cells, these cells are also more suppressive in a T cell proliferation assay.

CRIg has also been reported as a complement receptor ([@bib32]). However, our data reveal that the effects of CRIg in T cells can be exerted in a complement-independent manner. This suggests that complement components are not necessarily involved in CRIg-mediated suppression of effector T cells and differentiation of Treg cells.

CRIg emerges as a molecular link between environmental cues and adaptive immunity in controlling excessive tissue inflammation. The expression of CRIg in macrophages is dampened by inflammatory signals, such as lipopolysaccharide ([@bib58]). Loss of abundancy of CRIg^+^ macrophages is associated with exacerbated tissue inflammation in multiple autoimmune conditions ([@bib58]; [@bib22]). Therefore, identifying what signals induce or suppress the expression of CRIg in TRMs is essential for better understanding how TRMs sense environmental signals and in turn orchestrate the activities of T cells. We find that CRIg expression in TRMs is induced postnatally and the abundance of CRIg^+^ TRMs sharply increases around weaning, a time window allowing postnatal colonization of gut microbiota in mice ([@bib39]). The connection between gut microbiome and CRIg is evident from our studies showing that antibiotic treatment diminishes CRIg expression in TRMs at various locations, including colon, pancreas and peritoneal cavity. A recent study has demonstrated that antibiotic-mediated gut dysbiosis accelerated the development of T1D in mice ([@bib40]). The dampened expression of CRIg in pancreatic TRMs under dysbiotic conditions could be one plausible mechanism. Thus, environmental factors (most likely microbial signals and metabolites) instruct TRMs to express CRIg, which functions as an immune checkpoint molecule to regulate tissue T cell activities.

We found CRIg^+^ cells in human pancreas, suggesting a potential role of CRIg in human T1D. CRIg^+^ TRMs are also abundantly present in other gastrointestinal organs, including liver and intestines in both mice and humans ([@bib32]). It thus can be speculated that CRIg may also play a role in maintaining immunological homeostasis in these tissues.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                Designation                                    Source or reference          Identifiers                                                                                                                                                                          Additional information
  (species)\                                                                                                                                                                                                                                                                                                    
  or resources                                                                                                                                                                                                                                                                                                  
  -------------------------------------------- ---------------------------------------------- ---------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------
  strain, strain background (*Mus musculus*)   C57BL/6 (B6) mice                              The Jackson\                 RRID:[IMSR_JAX:000664](https://scicrunch.org/resolver/IMSR_JAX:000664)                                                                                                               
                                                                                              Laboratory                                                                                                                                                                                                        

  strain, strain background (*Mus musculus*)   NOD mice                                       Mathis-Benoist\              RRID:[IMSR_JAX:001976](https://scicrunch.org/resolver/IMSR_JAX:001976)                                                                                                               
                                                                                              laboratory                                                                                                                                                                                                        

  strain, strain background (*Mus musculus*)   NOD/Foxp3^GFP ^mice                            The Jackson\                 RRID:[IMSR_JAX:025097](https://scicrunch.org/resolver/IMSR_JAX:025097)                                                                                                               
                                                                                              Laboratory                                                                                                                                                                                                        

  strain, strain background (*Mus musculus*)   B6/CD45.1 mice                                 Dr. Li-Fan Lu, UCSD          RRID:[IMSR_JAX:002014](https://scicrunch.org/resolver/IMSR_JAX:002014)                                                                                                               

  strain, strain background (*Mus musculus*)   NOD/BDC2.5\                                    Mathis-Benoist\                                                                                                                                                                                                   
                                               /Thy1.1 mice                                   laboratory                                                                                                                                                                                                        

  strain, strain background (*Mus musculus*)   NOD/BDC2.5\                                    this paper                                                                                                                                                                                                        NOD/BDC2.5/Foxp3^GFP^/\
                                               /Foxp3^GFP^\                                                                                                                                                                                                                                                     Thy1.1 mice were generated by crossing\
                                               /Thy1.1 mice                                                                                                                                                                                                                                                     NOD/BDC2.5/Thy1.1 mice to NOD/\
                                                                                                                                                                                                                                                                                                                Foxp3^GFP^ mice.

  strain, strain background (*Mus musculus*)   NOD/BDC2.5\                                    this paper                                                                                                                                                                                                        NOD/BDC2.5/Foxp3^GFP^/\
                                               /Foxp3^GFP^\                                                                                                                                                                                                                                                     Thy1.1/Thy1.2\
                                               /Thy1.1/Thy1.2 mice                                                                                                                                                                                                                                              mice were generated by crossing\
                                                                                                                                                                                                                                                                                                                NOD/BDC2.5/Thy1.1 mice to NOD/Foxp3^GFP^ mice.

  strain, strain background (*Mus musculus*)   B6/CRIg KO mice                                Genentech                                                                                                                                                                                                         PMID: 16530040

  strain, strain background (*Mus musculus*)   NOD/CRIg KO mice                               this paper                                                                                                                                                                                                        NOD/CRIg^-/-^ mice were\
                                                                                                                                                                                                                                                                                                                generated by crossing B6/CRIg^-/-^\
                                                                                                                                                                                                                                                                                                                mice onto a NOD background for more\
                                                                                                                                                                                                                                                                                                                than 10 generations.

  biological sample (*Mus musculus*)           pancreas                                       other                                                                                                                                                                                                             prepared from NOD mice

  biological sample (*Mus musculus*)           colon lamina\                                  other                                                                                                                                                                                                             prepared from\
                                               propria                                                                                                                                                                                                                                                          NOD orB6 mice

  biological sample (*Mus musculus*)           peritoneal\                                    other                                                                                                                                                                                                             prepared from\
                                               cavity cells                                                                                                                                                                                                                                                     NOD or B6 mice

  biological sample (*Mus musculus*)           lung                                           other                                                                                                                                                                                                             prepared from NOD or B6 mice

  biological sample (*Mus musculus*)           liver                                          other                                                                                                                                                                                                             prepared from NOD or B6 mice

  biological sample (*Mus musculus*)           serum                                          other                                                                                                                                                                                                             prepared from\
                                                                                                                                                                                                                                                                                                                NOD mice

  biological sample (*Mus musculus*)           panLNs                                         other                                                                                                                                                                                                             pancreatic\
                                                                                                                                                                                                                                                                                                                draining lymph\
                                                                                                                                                                                                                                                                                                                nodes from NOD mice

  biological sample (*Mus musculus*)           ILNs                                           other                                                                                                                                                                                                             Inguinal\
                                                                                                                                                                                                                                                                                                                lymph nodes from\
                                                                                                                                                                                                                                                                                                                NOD or B6 mice

  biological sample (*Mus musculus*)           spleen                                         other                                                                                                                                                                                                             prepared from\
                                                                                                                                                                                                                                                                                                                NOD or B6 mice

  biological sample (*Mus musculus*)           macrophages                                    other                                                                                                                                                                                                             defined as F4/80^+^\
                                                                                                                                                                                                                                                                                                                or F4/80^+^ CD11b^+^ cells

  biological sample (*Mus musculus*)           Treg cells                                     other                                                                                                                                                                                                             defined as CD4^+^\
                                                                                                                                                                                                                                                                                                                Foxp3^+^ T cells

  biological sample (*Mus musculus*)           Tconv cells                                    other                                                                                                                                                                                                             defined as CD4^+^\
                                                                                                                                                                                                                                                                                                                Foxp3^-^ T cells

  antibody                                     Ultra-LEAF Purified\                           BioLegend                    RRID:[AB_11149115](https://scicrunch.org/resolver/AB_11149115)                                                                                                                       clone: 145--2C11
                                               anti-mouse CD3ε (Armenian hamster\                                                                                                                                                                                                                               
                                               monoclonal)                                                                                                                                                                                                                                                      

  antibody                                     Ultra-LEAF Purified\                           BioLegend                    RRID:[AB_11150408](https://scicrunch.org/resolver/AB_11150408)                                                                                                                       clone: 37.51
                                               anti-mouse CD28 (Syrian hamster\                                                                                                                                                                                                                                 
                                               monoclonal)                                                                                                                                                                                                                                                      

  antibody                                     anti-gp120\                                    Genentech                                                                                                                                                                                                         control Ig in this paper PMID: 16530040
                                               (mouse monoclonal)                                                                                                                                                                                                                                               

  antibody                                     anti-CRIg\                                     Genentech                                                                                                                                                                                                         clone: 14G8 (mouse monoclonal;\
                                                                                                                                                                                                                                                                                                                PMID: 19017980);\
                                                                                                                                                                                                                                                                                                                clone: 17C9 (rat monoclonal;\
                                                                                                                                                                                                                                                                                                                PMID: 16530040)

  antibody                                     anti-TGF-β 1, 2, 3\                            R and D Systems              RRID:[AB_357931](https://scicrunch.org/resolver/AB_357931)                                                                                                                           clone: 1D11
                                               (mouse monoclonal)                                                                                                                                                                                                                                               

  antibody                                     anti-CD16/CD32\                                BD Biosciences               RRID:[AB_394656](https://scicrunch.org/resolver/AB_394656)                                                                                                                           clone: 2.4G2
                                               (rat SD\                                                                                                                                                                                                                                                         
                                               monoclonal)                                                                                                                                                                                                                                                      

  antibody                                     anti-CRIg\                                     this paper                                                                                                                                                                                                        Biotinylated anti-CRIg (clone: 14G8) prepared\
                                               (mouse monoclonal)                                                                                                                                                                                                                                               by our laboratory

  antibody                                     anti-CD45\                                     BioLegend                    RRID:[AB_312981](https://scicrunch.org/resolver/AB_312981)                                                                                                                           clone: 30-F11
                                               (rat monoclonal)                                                                                                                                                                                                                                                 

  antibody                                     anti-CD45.1\                                   BioLegend                    RRID:[AB_893346](https://scicrunch.org/resolver/AB_893346)                                                                                                                           clone: A20
                                               (mouse monoclonal)                                                                                                                                                                                                                                               

  antibody                                     anti-CD45.2\                                   BioLegend                    RRID:[AB_389211](https://scicrunch.org/resolver/AB_389211)                                                                                                                           clone: 104
                                               (mouse monoclonal)                                                                                                                                                                                                                                               

  antibody                                     anti-TCRβ\                                     BioLegend                    RRID:[AB_493344](https://scicrunch.org/resolver/AB_493344)                                                                                                                           clone: H57-597
                                               (Armenian hamster\                                                                                                                                                                                                                                               
                                               monoclonal)                                                                                                                                                                                                                                                      

  antibody                                     anti-CD4\                                      BioLegend                    RRID:[AB_312719](https://scicrunch.org/resolver/AB_312719); RRID:[AB_312713](https://scicrunch.org/resolver/AB_312713); RRID:[AB_312715](https://scicrunch.org/resolver/AB_312715)   clone: RM4-5
                                               (rat monoclonal)                                                                                                                                                                                                                                                 

  antibody                                     anti-CD8α\                                     BioLegend                    RRID:[AB_312747](https://scicrunch.org/resolver/AB_312747); RRID:[AB_312761](https://scicrunch.org/resolver/AB_312761)                                                               clone: 53--6.7
                                               (rat monoclonal)                                                                                                                                                                                                                                                 

  antibody                                     anti-Thy1.1\                                   BioLegend                    RRID:[AB_961437](https://scicrunch.org/resolver/AB_961437)                                                                                                                           clone: OX-7
                                               (mouse monoclonal)                                                                                                                                                                                                                                               

  antibody                                     anti-Thy1.2\                                   BioLegend                    RRID:[AB_492888](https://scicrunch.org/resolver/AB_492888)                                                                                                                           clone: 30-H12
                                               (rat monoclonal)                                                                                                                                                                                                                                                 

  antibody                                     anti-Helios (Armenian hamster monoclonal)      BioLegend                    RRID:[AB_10660749](https://scicrunch.org/resolver/AB_10660749)                                                                                                                       clone: 22F6

  antibody                                     anti-ICOS (rat monoclonal)                     ebioscience                  RRID:[AB_2573563](https://scicrunch.org/resolver/AB_2573563)                                                                                                                         clone: 7E.17G9

  antibody                                     anti-CD122 (rat monoclonal)                    BioLegend                    RRID:[AB_313226](https://scicrunch.org/resolver/AB_313226)                                                                                                                           clone: 5H4

  antibody                                     anti-CD25 (rat monoclonal)                     BioLegend                    RRID:[AB_312857](https://scicrunch.org/resolver/AB_312857); RRID:[AB_312865](https://scicrunch.org/resolver/AB_312865)                                                               clone: PC61

  antibody                                     anti-CD69 (Armenian hamster monoclonal)        BioLegend                    RRID:[AB_2260065](https://scicrunch.org/resolver/AB_2260065)                                                                                                                         clone: H1.2F3

  antibody                                     anti-CDF4/80 (rat monoclonal)                  BioLegend                    RRID:[AB_893481](https://scicrunch.org/resolver/AB_893481)                                                                                                                           clone: BM8

  antibody                                     anti-CD11b (rat monoclonal)                    BioLegend                    RRID:[AB_312791](https://scicrunch.org/resolver/AB_312791); RRID:[AB_755986](https://scicrunch.org/resolver/AB_755986)                                                               clone: M1/70

  antibody                                     anti-CD11c (Armenian hamster monoclonal)       BioLegend                    RRID:[AB_313777](https://scicrunch.org/resolver/AB_313777)                                                                                                                           clone: N418

  antibody                                     anti-CD19 (rat monoclonal)                     BioLegend                    RRID:[AB_313643](https://scicrunch.org/resolver/AB_313643)                                                                                                                           clone: 6D5

  antibody                                     anti-NKp46 (rat monoclonal)                    BioLegend                    RRID:[AB_2235755](https://scicrunch.org/resolver/AB_2235755)                                                                                                                         clone: 29A1.4

  antibody                                     anti-IL-17 (rat monoclonal)                    BioLegend                    RRID:[AB_536018](https://scicrunch.org/resolver/AB_536018)                                                                                                                           clone: TC11-18H10.1

  antibody                                     anti-IFN-γ\                                    BioLegend                    RRID:[AB_315402](https://scicrunch.org/resolver/AB_315402)                                                                                                                           clone: XMG1.2
                                               (rat monoclonal)                                                                                                                                                                                                                                                 

  antibody                                     anti-Foxp3\                                    ebioscience                  RRID:[AB_1518812](https://scicrunch.org/resolver/AB_1518812)                                                                                                                         clone: FJK-16s
                                               (rat monoclonal)                                                                                                                                                                                                                                                 

  antibody                                     anti-phospho\                                  ebioscience                  RRID:[AB_2572664](https://scicrunch.org/resolver/AB_2572664)                                                                                                                         clone: n3kobu5
                                               ZAP70/Syk^Tyr319/Tyr352^ (mouse monoclonal)                                                                                                                                                                                                                      

  antibody                                     anti-phospho\                                  BioLegend                    RRID:[AB_2629710](https://scicrunch.org/resolver/AB_2629710)                                                                                                                         clone: 6B8B69
                                               ERK1/2^Thr202/Tyr204^ (mouse monoclonal)                                                                                                                                                                                                                         

  antibody                                     anti-phospho AKT1^Ser473^ (mouse monoclonal)   ebioscience                  RRID:[AB_2573309](https://scicrunch.org/resolver/AB_2573309)                                                                                                                         clone: SDRNR

  antibody                                     anti-phospho\                                  ebioscience                  RRID:[AB_2572666](https://scicrunch.org/resolver/AB_2572666)                                                                                                                         clone: cupk43k
                                               S6^Ser235,\ Ser236^ (mouse monoclonal)                                                                                                                                                                                                                           

  antibody                                     anti-phospho STAT5 (mouse monoclonal)          BD Biosciences               RRID:[AB_10894188](https://scicrunch.org/resolver/AB_10894188)                                                                                                                       clone: 47/Stat5(pY694)

  antibody                                     anti-phospho Smad2 (pS465/pS467)/\             BD Biosciences               RRID:[AB_2716578](https://scicrunch.org/resolver/AB_2716578)                                                                                                                         clone: O72-670
                                               Smad3 (pS423/pS425) (mouse monoclonal)                                                                                                                                                                                                                           

  antibody                                     PerCP/Cy5.5-streptavidin                       BioLegend                    RRID:[AB_2716577](https://scicrunch.org/resolver/AB_2716577)                                                                                                                         

  recombinant DNA reagent                      pCR 2.1-TOPO (vector)                          Invitrogen                   CAT\#: K204040                                                                                                                                                                       

  sequence-based reagent                       Foxp3 Intron1                                  Eton Bioscience                                                                                                                                                                                                   Forward: ATTTGAATTGGATATGGTTTGT; Reverse: AACCTTAAACCCCTCTAACATC

  sequence-based reagent                       Foxp3 TSDR                                     Eton Bioscience                                                                                                                                                                                                   Forward: GTTTGTGTTTTTGAGATTTTAAAAT; Reverse: AACCAACTTCCTACACTATCTATTA

  sequence-based reagent                       Rara                                           Eton Bioscience                                                                                                                                                                                                   Forward: CCAGTCAGTGGTTACAGCACA; Reverse: TAGTGGTAGCCGGATGATTTG

  sequence-based reagent                       Rarb                                           Eton Bioscience                                                                                                                                                                                                   Forward: ACATGATCTACACTTGCCATCG; Reverse: TGAAGGCTCCTTCTTTTTCTTG

  sequence-based reagent                       Rarg                                           Eton Bioscience                                                                                                                                                                                                   Forward: CATTTGAGATGCTGAGCCCTA; Reverse: GCTTATAGACCCGAGGAGGTG

  sequence-based reagent                       Oligo(dT)~12-18~ Primer                        Invitrogen                   CAT\#: 18418012                                                                                                                                                                      

  peptide, recombinant protein                 CRIg-Ig                                        Genentech                                                                                                                                                                                                         PMID: 16530040

  peptide, recombinant protein                 Biotinylated CRIg-Ig                           this paper                                                                                                                                                                                                        prepared by our\
                                                                                                                                                                                                                                                                                                                laboratory

  peptide, recombinant protein                 control Ig                                     Genentech                                                                                                                                                                                                         PMID: 16530040

  peptide, recombinant protein                 Biotinylated\                                  this paper                                                                                                                                                                                                        prepared by our laboratory
                                               control Ig                                                                                                                                                                                                                                                       

  peptide, recombinant protein                 CTLA-4 Ig                                      R and D Systems              CAT\#: 434-CT-200/CF                                                                                                                                                                 

  peptide, recombinant protein                 PD-1 Ig                                        R and D Systems              CAT\#: 1021-PD-100                                                                                                                                                                   

  peptide, recombinant protein                 VISTA Ig                                       R and D Systems              CAT\#: 7005-B7-050                                                                                                                                                                   

  peptide, recombinant protein                 CD226 Ig                                       R and D Systems              CAT\#: 4436-DN-050                                                                                                                                                                   

  peptide, recombinant protein                 TIGIT Ig                                       R and D Systems              CAT\#: 7267-TG-050                                                                                                                                                                   

  peptide, recombinant protein                 BDC2.5 mimotope                                AnaSpec                      CAT\#: AS-63774                                                                                                                                                                      Sequence: RTRPLWVRME

  peptide, recombinant protein                 Recombinant\                                   PeproTech                    CAT\#: 212--12                                                                                                                                                                       
                                               Murine IL-2                                                                                                                                                                                                                                                      

  peptide, recombinant protein                 Recombinant Human\                             PeproTech                    CAT\#: 100--21                                                                                                                                                                       
                                               TGF-β1                                                                                                                                                                                                                                                           

  commercial assay or kit                      ACK lysing buffer                              Lonza                        CAT\#: 10-548E                                                                                                                                                                       

  commercial assay or kit                      Anti-PE microBeads                             Miltenyi Biotec              CAT\#: 130-048-801                                                                                                                                                                   

  commercial assay or kit                      LIVE/DEAD fixable\                             Invitrogen                   CAT\#: L34972; CAT\#: L34966                                                                                                                                                         
                                               dead cell stain kits                                                                                                                                                                                                                                             

  commercial assay or kit                      Foxp3/Transcription\                           ebioscience                  CAT\#: 00-5523-00                                                                                                                                                                    
                                               factorstaining buffer set                                                                                                                                                                                                                                        

  commercial assay or kit                      Phosflow\                                      BD Biosciences               CAT\#: 558049                                                                                                                                                                        
                                               Lyse/Fix buffer                                                                                                                                                                                                                                                  

  commercial assay or kit                      Phosflow\                                      BD Biosciences               CAT\#: 558050                                                                                                                                                                        
                                               Perm buffer III                                                                                                                                                                                                                                                  

  commercial assay or kit                      Percoll                                        GE Healthcare Life Science   CAT\#: 17-0891-01                                                                                                                                                                    

  commercial assay or kit                      NucleoSpin\                                    Macherey-Nagel               CAT\#: 740901.50                                                                                                                                                                     
                                               Tissue XS                                                                                                                                                                                                                                                        

  commercial assay or kit                      EZ DNA\                                        Zymo Research                CAT\#: D5001                                                                                                                                                                         
                                               Methylaiton Kit                                                                                                                                                                                                                                                  

  commercial assay or kit                      HotStarTaq\                                    QIAGEN                       CAT\#: 203203                                                                                                                                                                        
                                               DNA Polymerase                                                                                                                                                                                                                                                   

  commercial assay or kit                      TOPO TA Cloning Kit                            Invitrogen                   CAT\#: K204040                                                                                                                                                                       

  commercial assay or kit                      TRIzol Reagent                                 Invitrogen                   CAT\#: 15596026                                                                                                                                                                      

  commercial assay or kit                      SuperScript III\                               Invitrogen                   CAT\#: 18080044                                                                                                                                                                      
                                               Reverse Transcriptase                                                                                                                                                                                                                                            

  commercial assay or kit                      SYBR Green\                                    Applied Biosystems           CAT\#: 4309155                                                                                                                                                                       
                                               PCR Master Mix                                                                                                                                                                                                                                                   

  chemical compound, drug                      Collagenase P                                  Roche                        CAT\#: 11249002001                                                                                                                                                                   

  chemical compound, drug                      Collagenase D                                  Roche                        CAT\#: 11088882001                                                                                                                                                                   

  chemical compound, drug                      DNase I                                        Sigma-Aldrich                CAT\#: DN25-1G                                                                                                                                                                       

  chemical compound, drug                      ATRA                                           Sigma-Aldrich                CAT\#: R2625-50MG                                                                                                                                                                    

  chemical compound, drug                      BMS 493                                        Sigma-Aldrich                CAT\#: B6688-5MG                                                                                                                                                                     

  chemical compound, drug                      Vancomycin                                     Acros Organics               CAT\#: 296990010                                                                                                                                                                     

  chemical compound, drug                      Metronidazole                                  Acros Organics               CAT\#: 210340050                                                                                                                                                                     

  chemical compound, drug                      Neomycin                                       Fisher Scientific            CAT\#: BP266925                                                                                                                                                                      

  chemical compound, drug                      Ampicillin                                     Sigma-Aldrich                CAT\#: A0166-25G                                                                                                                                                                     

  chemical compound, drug                      PMA                                            Sigma-Aldrich                CAT\#: P1585-1MG                                                                                                                                                                     

  chemical compound, drug                      Ionomycin                                      Sigma-Aldrich                CAT\#: I0634-1MG                                                                                                                                                                     

  chemical compound, drug                      Brefeldin A solution                           BioLegend                    CAT\#: 420601                                                                                                                                                                        

  chemical compound, drug                      Fisher Healthcare\                             Fisher Scientific            CAT\#: 23-730-571                                                                                                                                                                    
                                               Tissue-Plus O.C.T Compound                                                                                                                                                                                                                                       

  chemical compound, drug                      Avidin, HRP conjugate                          Invitrogen                   CAT\#: 434423                                                                                                                                                                        

  chemical compound, drug                      1-Step Ultra TMB-ELISA\                        Thermo Scientific            CAT\#: 34028                                                                                                                                                                         
                                               Substrate Solution                                                                                                                                                                                                                                               

  chemical compound, drug                      Stop Solution for\                             Thermo Scientific            CAT\#: N600                                                                                                                                                                          
                                               TMB Substrates                                                                                                                                                                                                                                                   

  chemical compound, drug                      DAPI                                           Invitrogen                   CAT\#: D1306                                                                                                                                                                         

  software, algorithm                          FlowJo                                         FlowJo, LLC                  RRID:[SCR_008520](https://scicrunch.org/resolver/SCR_008520)                                                                                                                         

  software, algorithm                          ImageJ                                         NIH                          RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)                                                                                                                         

  software, algorithm                          BISMA software                                 other                        RRID:[SCR_000688](https://scicrunch.org/resolver/SCR_000688)                                                                                                                         public website, BDPC DNA methylation analysis platform
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

B6 and NOD/Foxp3^GFP^ mice ([@bib28]) were purchased from Jackson laboratory. NOD and NOD/BDC2.5/Thy1.1 mouse lines were obtained from Mathis-Benoist laboratory ([@bib33]). NOD/BDC2.5/Thy1.1 mice were further crossed to NOD/Foxp3^GFP^ to generate NOD/BDC2.5/Foxp3^GFP^/Thy1.1^+^ and NOD/BDC2.5/Foxp3^GFP^ Thy1.1^+^ Thy1.2^+^ mice. B6/CRIg KO mice were provided by Genentech ([@bib32]). NOD/CRIg KO mice were generated by crossing B6/CRIg KO mice onto a NOD background for more than 10 generations. Speed-congenics was used to facilitate the generation of NOD/CRIg KO mice. All mice were housed under specific pathogen free (SPF) conditions in our animal facility at University of California, San Diego, in accordance with the ethical guidelines of the Institutional Animal Care and Use Committee.

Cell preparations {#s4-2}
-----------------

The pancreas was minced and digested in 10 ml phenol red-free Dulbecco\'s modiﬁed Eagle\'s medium (DMEM) containing collagenase P (0.5 mg/ml) (Roche, Indianapolis, IN) at 37°C on a 200 rpm shaker for 20 min. After digestion, single cells were filtered by passing through a 70 um cell strainer and suspended in FACS staining buffer. Colon lamina propria (cLP) cells were prepared as previously described. Briefly, the intestine was cut longitudinally and sliced into 0.2--0.5 cm pieces, followed by incubating in 10 ml Ca2^+^/Mg2^+^ free HBSS containing 10% FBS, 15 mM HEPES, and 5 mM EDTA at 37°C on a 200 rpm shaker for 20 min. The intestine fragments were further digested in 10 ml RPMI 1640 containing 5% FBS, Collagenase D (0.5 mg/ml) (Roche) and DNase I (0.05 mg/ml) (Sigma-Aldrich, Saint Louis, MO) at 37°C on a 200 rpm shaker for 45 min. Samples were collected by passing through a 70 um cell strainer. cLP cells were then purified on a 44/67% Percoll (GE Healthcare Life Science, Chicago, IL) gradient by centrifugation (800 x g, 20 min at room temperature). Single-cell suspensions of lymphoid organs were prepared by mechanic disruption. Red blood cells were lysated with Ammonium-Chloride-Potassium (ACK) buffer (Lonza, Walkersville, MD). Peritoneal cells were collected by flushing 1 x PBS into the peritoneal cavity.

In vitro T cell activation {#s4-3}
--------------------------

For T cell activation assays, 96-well tissue-culture plates were pre-coated with anti-CD3 (2.5 ug/ml) and CRIg-Ig (5 ug/ml), or control Ig in 1 x PBS at 4°C overnight. The plates were washed with 1 x PBS three times. Single cell suspensions from spleen, peripheral lymph node were prepared. CD4^+^ CD25^-^ cells were MACS (Miltenyi Biotec, Auburn, CA) enriched and labeled with CFSE or CTV. In some experiments, CD4^+ ^Foxp3(GFP)^-^ Tconv cells were FACS sorted. Isolated Tconv cells (1 × 10^5^/well) were cultured in RPMI1640 supplemented with 10% FBS, L-glutamine (2 mM), penicillin (100 U/ml), streptomycin (100 ug/ml), and non-essential amino acids (100 Um) and β-mercaptoethanol (50 uM), in the presence of soluble anti-CD28 (2.5 ug/ml). CRIg-Ig fusion proteins were pre-coated or added as soluble form as indicated. In some experiments, anti-CRIg mAb (clone 17C9, or 14G8) was added to the culture either in a soluble form, or pre-coated as indicated. To test the effect of cross-linking of CRIg by anti-CRIg mAb, plates were pre-coated with different concentrations of anti-CRIg mAb (clone 17C9), or isotype control mAb, and anti-CD3. Soluble anti-CD28 and soluble CRIg-Ig (5 ug/ml) were added to the cultured cells.

In vitro iTreg differentiation and restimulation {#s4-4}
------------------------------------------------

96-well tissue-culture plates were pre-coated with either CRIg-Ig (2.5 ug/ml), or control Ig. CD4^+^ Foxp3^-^ Tconv cells were sorted from NOD/Foxp3^GFP^ reporter mice, labeled with CFSE or CTV and cultured (1 × 10^5^) in the presence of plate-bound anti-CD3 (2.5 ug/ml), soluble anti-CD28 (2.5 ug/ml), murine IL-2 (100 U/ml) and TGF-β (1 ng/ml or as indicated) for 3 days. In some experiments, an anti-TGF-β neutralizing antibody (clone 1D11) was added. In antigen-stimulated Treg differentiation assays, the plates were pre-coated with either CRIg-Ig (10 ug/ml), or control Ig. Total splenocytes (2 × 10^5^) from NOD/BDC2.5/Thy1.1 mice were labeled with CTV and cultured with mimotope (100 ng/ml) (AnaSpec, Fremont, CA) for 3 days. Cells were then analyzed for the expression of GFP or intracellular staining for Foxp3.

For the culture of restimulated iTreg cells, iTreg cells were generated by TGF-β, without CRIg-Ig. After 24 hr, GFP (Foxp3)^+^ cells were sorted and restimulated under the condition of plate-bound anti-CD3 (2.5 ug/ml), soluble anti-CD28 (2.5 ug/ml), IL-2 (100 U/ml), anti-TGF-β neutralizing antibody (clone 1D11), with plate-bound CRIg-Ig (5 ug/ml) or control Ig, respectively. After 3 days, cultured cells were collected and analyzed for the expression of GFP or intracellular staining for Foxp3. In some experiments, purified Tconv cells were activated for 24 hr, washed and transferred to a new plate with coated anti-CD3 (2.5 ug/ml), soluble anti-CD28 (2.5 ug/ml), IL-2 (100 U/ml) and TGF-β (1 ng/ml) and cultured for 3 days.

For in vitro Treg suppression assay, iTreg cells were generated as above with CRIg-Ig, or Control-Ig, respectively. After 3 days, GFP (Foxp3)^+^ cells were sorted and co-cultured with MACS enriched CTV labeled CD4^+^CD25^-^ cells at the ratio of 1:4, 1:2 and 1:1, respectively, in the presence of plate-bound anti-CD3, soluble anti-CD28 for 3 days.

In vitro macrophage culture {#s4-5}
---------------------------

F4/80^+^ macrophages from peritoneal cavity were sorted as CRIg^+^ or CRIg^-^ subsets and cultured in complete DMEM in the presence of RA (100 nM) (Sigma-Aldrich) or control DMSO. After 3 days of culture, adherent macrophages were harvested by adding Trypsin and EDTA (5 mM) and analyzed for CRIg expression by FACS.

Adoptive cell transfer and in vivo treatments {#s4-6}
---------------------------------------------

For in vivo CRIg-Ig treatment, 10-week-old pre-diabetic NOD mice were *i.p.* injected with CRIg-Ig (3.5 mg/kg) mixed with anti-CRIg mAb (17C9) (7 mg/kg) or control Ig (3.5 mg/kg), twice a week for 2 weeks. Pancreas and other lymphoid organs were analyzed after the treatment. For in vivo pTreg induction assays, CD4^+ ^Foxp3(GFP)^-^ Tconv cells were sorted from NOD/BDC2.5/Foxp3^GFP^/Thy1.1^+^ mice and *i.p.* transferred to 4-week-old NOD or NOD/CRIg KO mice. In some experiments, NOD mice received adoptively transferred Tconv cells were injected with CRIg-Ig, or control Ig every other day for 2 weeks. After 2 weeks, transferred cells collected from the pancreas and lymphoid organs were analyzed. For in vivo iTreg stability assays, CD4^+^ Foxp3(GFP)^-^ Tconv cells were sorted from NOD/Foxp3^GFP^/Thy1.1^+^ mice, or NOD/Foxp3^GFP^/Thy1.1^+^ Thy1.2^+^ mice, and differentiated into iTreg cells under conditions with plate-bound CRIg-Ig and control Ig respectively. iTreg cells from these two conditions were sorted and mixed (2 × 10^5^ each) at 1:1 ratio before transferring into 10--14 days old NOD mice (Thy1.2^+^). One week later, transferred cells from spleen and pancreatic islets were isolated and analyzed by flow cytometry. For antibiotics treatment, 8-week-old B6, or 10-week-old NOD mice were given a combination of four antibiotics (vancomycin, metronidazole, neomycin and ampicillin, VMNA) ([@bib48]) in drinking water supplement with sugar. Peritoneal cavity, pancreatic and colonic macrophages were analyzed one week later. For in vivo treatment of BMS 493 (Sigma-Aldrich), 7 weeks old B6 mice were *i.p.* injected with BMS 493 (100 nM) daily for 3 days. In some experiments, peritoneal cavity macrophages (3 × 10^4^) were sorted from B6/CD45.1 mice and *i.p.* transferred into B6/CD45.2 mice, followed by BMS 493 treatment. Peritoneal and pancreatic macrophages were analyzed after the last injection.

Abs and flow cytometry {#s4-7}
----------------------

All stainings began with an incubation with a mAb for CD16/32 (2.4G2 BD Biosciences). mAbs to indicated molecules used in this study were: Biotin-CRIg were prepared by our laboratory. CD45 (30-F11), CD45.1 (A20), CD45.2 (104), TCRβ (H57-597), CD4 (RM4-5), CD8α (53--6.7), Thy1.1 (OX-7), Thy1.2 (30-H12), Helios (22F6), CD122 (5H4), CD25 (PC61), CD69 (H1.2F3), F4/80 (BM8), CD11b (M1/70), CD11c (N418), CD19 (6D5), NKp46 (29A1.4), IL-17 (TC11-18H10.1), and IFN-γ (XMG1.2) from BioLegend (San Diego, CA); ICOS (7E.17G9) and Foxp3 (FJK-16s) from eBioscience (San Diego, CA) . PerCP/Cy5.5-streptavidin was from BioLegend. Intracellular staining of Foxp3 and Helios was performed using Foxp3/transcription factor staining buffer set (eBioscience) according to the manufacturer's instructions. For intracellular IFN-γ and IL-17 detection, unfractionated cells were cultured in complete medium in the presence of phorbol myristate acetate (PMA), and Ionomycin (Signa-Aldrich) and Brefeldin A (BioLegend) at 37°C for 4 hr. Samples were acquired with a BD LSRFortessa (BD, San Jose, CA) and analyzed with FlowJo software (FlowJo, LLC, Ashland, OR).

Binding assays {#s4-8}
--------------

CD4^+^ CD25^-^ Tconv cells from 10-week-old NOD mice, or CD4^+^ GFP(Foxp3)^+^ Treg cells from 10-week-old NOD/Foxp3^GFP^ mice, were cultured under the in vitro T cell activation condition. At indicated time-points, different concentrations of biotinylated CRIg-Ig or control Ig were incubated with cultured T cells at 37°C for 1 hr. Cells were then harvested and stained with Fixable Viability Dyes (Invitrogen, Carlsbad, CA) before fixed with paraformaldehyde (1.6%). Streptavidin-conjugated secondary Abs were added to measure the binding intensities of biotinylated CRIg-Ig or control Ig.

Enzyme-linked immunosorbent assay {#s4-9}
---------------------------------

Flat bottom Costar 96-well plate were coated with 100 ul rat anti-mouse CRIg (clone 19E4, 1 ug/ml) in 0.05 M Na~2~CO~3~ pH 9.6 at 4°C overnight. Coated Plates were washed with 1 x PBS and blocked with blocking buffer which contains 50 mM Tris, 0.14 M NaCl, and 1% BSA at 37°C for 2 hr. Mice sera were diluted (1:20) and 100 ul of sample was added to each well and incubated at 37°C for 2 hr. After incubation, plates were washed with 1x PBS containing 50 mM Tris, 0.14 M NaCl, 0.05% Tween 20, and incubated with 100 ul 1 ug/ml biotinylated anti-CRIg mAb (14G8) in blocking buffer at 37°C for 1 hr. After washing, plates were then incubated with diluted HRP-Avidin (1: 20,000) (Invitrogen) at 37°C for 1 hr. Plates were washed and incubated with TMB substrate at 37°C for 30 min. Stop solution was added before plates were read on microplate reader at an optical density (O.D.) of 450 nm (reference 570 nm).

Phosphorylation assays {#s4-10}
----------------------

CD4^+^ CD25^-^ cells were cultured under the in vitro T cell activation conditions. At indicated time pointes, the cells were fixed with paraformaldehyde (1.6%) for 10 min at 37°C. Fixed cells were permeabilized with ice-cold methanol for 30 min, and stained with the phospho Abs for ZAP70^Tyr319/Tyr352^ (clone n3kobu5; eBioscience), ERK1/2^Thr202/Tyr204^ (clone 6B8B69; BioLegend), AKT1^Ser473^ (clone SDRNR; eBioscience) and S6^Ser235/236^(clone cupk43k; eBioscience) for 1 hr at room temperature. In Treg phosphorylation assays, control or CRIg iTreg cells were prepared as above described. After 18 hr, iTreg cells were fixed, permeabilized, and stained with phospho Abs for Akt^Ser473^, S6^Ser235/236^. For the analysis of phospho-STAT5, iTreg cells first rested in complete RPMI1640 medium for 30 min and then incubated with murine IL-2 (100 U/ml) for 15 min at 37°C. After that, the cells were fixed and permeabilized as described above and subsequently stained with anti-phospho-STAT5 (clone 47/Stat5(pY694); BD Biosciences) for 1 hr at room temperature. To detect the phosphor Smad2/3, total splenocytes from NOD mice were serum-starved overnight. CD4^+^ CD25^-^ cells were then sorted and cultured in medium with 0.2% of fetal bovine serum under iTreg differentiation condition. At indicated time-points, cultured T cells were fixed in Phosflow Lyse/Fix Buffer (BD Biosciences) for 10 min at 37°C and permeabilized in Phosflow Perm Buffer III (BD Biosciences) for 30 min on ice. Cells were then stained with mouse anti-Smad2 (pS465/pS467)/Smad3 (pS423/pS425) (O72/670; BD Biosciences) mAb for 1 hr at room temperature.

Immunostaining and histology {#s4-11}
----------------------------

Tissue samples were cut and snap frozen in optimum cutting temperature (O.C.T., Fisher Scientific, Houston, TX). 6 um cryo-sections of tissue sections were cut and fixed with pre-cold acetone for 20 min. Immunostaining was performed as previously described ([@bib21]). Before adding primary mAbs, sections were blocked with 5% normal donkey serum (Jackson ImmunoResearch, West Grove, PA). The following mAbs were used in different combinations as indicated in the figure legends: anti-CRIg mAb (a gift from Genentech, South San Francisco, CA); anti-F4/80 (BM8, BioLegend); anti-CD4 (RM4-5, BioLegend). Nuclei were stained with DAPI (4\',6-Diamidino-2--28 phenylindole dihydrochloride) (Invitrogen). Images were acquired on an AxioImager microscope (Zeiss, Thornwood, NY), and were processed with ImageJ (NIH). For histology assays, the pancreases were removed and fixed with 10% formalin solution. Fixed tissue blocks were paraffin-embedded, sectioned, and stained with haematoxylin and eosin.

Bisulfite sequencing {#s4-12}
--------------------

Genomic DNA was extracted by using NucleoSpin Tissue XS (Macherey-Nagel, Bethlehem, PA) and bisulfite converted by using the EZ DNA Methylation Kit (Zymo Research, Irvine, CA). Foxp3 CNS2 region was amplified by PCR containing 5 ng of bisulfite-converted genomic DNA, HotStar Taq PCR buffer (QIAGEN, Valencia, CA), 0.5 U HotStar Taq DNA polymerase, 2.5 mM MgCl~2~ and 0.38 μM each of forward and reverse primers ([@bib44]; [@bib61]) in a final volume of 25 μl (95°C for 10 min; 40 cycles: 95°C for 30 s, 58°C for 1 min, 72°C for 1 min; 72°C for 5 min). The PCR product was analyzed by gel electrophoresis and TA cloned using TOPO TA Cloning Kit (Invitrogen) and One Shot TOP10 Chemically Competent E. coli. Colonies were picked and submitted for direct colony sequencing. Sequencing results were analyzed on Bisulfite Sequencing DNA Methylation Analysis website ([@bib47]).

Real time RT-PCR {#s4-13}
----------------

CRIg^+^ and CRIg^-^ macrophages from the peritoneal cavity of 7-week-old B6 mice were FACS sorted. Total RNA was extracted using Trizol and reverse-transcribed using oligo(dT) and SuperScript III (Invitrogen). PCR was performed using Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA), using CFX96 Touch Real-Time PCR Detection System (Bio-Rad, Hercules, CA) for PCR and signal detection. The primers were: Rara forward: ccagtcagtggttacagcaca. Rara reverse: tagtggtagccggatgatttg. Rarb forward: acatgatctacacttgccatcg. Rarb reverse: tgaaggctccttctttttcttg. Rarg forward: catttgagatgctgagcccta. Rarg reverse: gcttatagacccgaggaggtg.

Statistics {#s4-14}
----------

Student's t-test was used for statistical analyses. *P* values of 0.05 or less were considered statistically significant.
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Thank you for submitting your article \"CRIg, a tissue-resident macrophage specific coinhibitory molecule, promotes immunological tolerance via a dual role in effector and regulatory T cells\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Tadatsugu Taniguchi as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The manuscript by Yuan, et al. describes a role of the complement receptor of immunoglobulin family (CRIg), which is exclusively expressed by tissue macrophages, in the induction of peripheral Foxp3-expressing Treg cells. The authors demonstrated that CRIg directly acted on an unknown ligand/receptor of activated T cells, promoting and stabilizing the differentiation of Treg cells via regulating IL-2 signaling pathways. Micro-environmental cues in the gut, including microbiota and metabolites (retinoic acid), were shown to control the expression of CRIg on tissue macrophages, leading to the induction of Treg-mediated immunological tolerance.

Essential revisions:

1\) It has been reported that CRIg plays a key role in tolerance induction. One major advance claimed by the paper is the promotion and stabilization of Foxp3^+^ peripheral Tregs by CRIg. However, the authors mainly used a CRIg-Ig fusion protein in their experiments to induce Treg cells and tolerance, which may be artificial. They should purify CRIg^+^ macrophages and coculture them with activated Th cells to test whether the macrophages with physiological levels of CRIg can specifically induce Foxp3^+^ Tregs.

2\) It was shown that CRIg-Ig promoted iTreg differentiation in vitro, but the authors should address whether CRIg^+^ macrophages could directly induce pTregs in in vivo settings. This will strengthen their claims. The frequency of Tregs in the pancreas was reduced in CRIg^-/-^ NOD as shown in [Figure 1C](#fig1){ref-type="fig"}. However, this experimental system does not exclude a possibility of indirect contribution of CRIg to the expansion of pTregs.

In addition, regarding [Figure 1](#fig1){ref-type="fig"}, how did the authors investigate the percentages of CRIg^+^ macrophages and each T cell population in pancreas? Additionally, the authors seemed to isolate cells from pancreatic islets selectively, but how did they do this? There seems to be no explanation for these procedures in the manuscript.

3\) Relating to the above point, where do pancreatic CRIg^+^ macrophages interact with activated Tconv cells and convert them into pTregs? Is there co-localization of CRIg^+^ macrophages and converted Foxp3^+^ Tregs in the pancreas?

4\) In [Figure 2D](#fig2){ref-type="fig"}, CRIg-Ig binding to activated Tconv is shown, but staining intensity is marginal and not convincing. More kinetics and control cells should be taken. In addition, expression levels of CRIg on thymic, peripheral, and in vitro induced Tregs need to be examined.

5\) With CRIg^-/-^ BL6 mice, are the findings in NOD mice also the case in BL6 mice? Since macrophages from various tissues express CRIg, the authors should examine whether CRIg^-/-^ mice have reduced frequencies of Tregs in mucosal tissues such as the gut, peritoneum, skin, and lung, where CRIg^+^ tissue macrophages are present.

6\) The rationale for the CRIg/C3 blockade experiments in [Figure 2](#fig2){ref-type="fig"} supplements. is unclear. A combination of CRIg-Ig and anti-CRIg completely blocked the proliferation of T conv cells. Although the authors assume that anti-CRIg can block the binding of CRIg to C3 components, this unexplained strong effect of anti-CRIg on T cell suppression is a bit odd. Are active C3 components present in this culture medium? Why does anti-CRIg induce a sort of super agonistic effect of CRIg? On the other hand, this complete T cell proliferation arrest ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) with CRIg and anti-CRIg contradicts with other results ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}) in which T cells robustly proliferate in the presence of CRIg and anti-CRIg.

7\) In [Figure 3E](#fig3){ref-type="fig"}, the differentiation of pTregs from Tconv was impaired in the pancreas, but not in LNs of CRIg^-/-^ NOD mice which had received adoptive transfer of BDC2.5 Tconv. This is a bit odd. It is unlikely that there is enough cellular niche to allow Tconv to get activated, expand, and differentiate into pTreg in T cell-sufficient NOD mice. They should show more detailed FACS profiles, for example, the proportion of Thy1.1 (transferred) vs Thy1.2 (resident) in Foxp3^+^ Tregs in the pancreas and LNs.

Also, CRIg-Ig treatment enhanced pTreg generation in pancreas but not in panLNs and ILNs in [Figure 3D](#fig3){ref-type="fig"}. The authors should discuss the reason for this result.

8\) Is the target molecule of CRIg on effector T cells and regulatory T cells same or different? The authors should discuss how CRIg exhibit opposite effects on the two different T cell populations.

9\) It is hard to understand why the authors focused on environmental factors that modulate CRIg expression on TRMs in the tissues other than pancreas. Is there any relationship between CRIg levels in pancreatic TRMs and bacterial colonization or RA? How about the expression of CRIg in pancreatic TRMs after birth in wild-type and NOD mice? It is more valuable for this study to find the environmental cues that would regulate CRIg levels in pancreatic TRMs, if possible, especially during the development of type 1 diabetes.

10\) Does CRIg bind to Treg and synergize with TGFb? Binding of CRIg to Tregs should be added (as in [Figure 2D](#fig2){ref-type="fig"} for activated T cells) along with key controls.

11\) Treg stability depends on the methylation status of FoxP3 CNS2 region. The authors have shown that CRIg does not affect the methylation status of CNS2 site of Foxp3 yet FoxP3 expression in adoptively transferred iTregs generated with CRIg-Ig is remarkably stable. The inference from this observation is that Tregs do not need continuous cell:cell contact with CRIg-expressing macrophages to maintain FoxP3 expression and function. The authors should discuss this point.

12\) The experiments in [Figures 6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"} are interesting and compelling. However they do not connect well with the rest of the paper. These features should have been examined in pancreatic macrophages to make [Figures 6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"} cohesive with [Figures 1](#fig1){ref-type="fig"}-5.
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Author response

> Essential revisions:
>
> 1\) It has been reported that CRIg plays a key role in tolerance induction. One major advance claimed by the paper is the promotion and stabilization of Foxp3^+^ peripheral Tregs by CRIg. However, the authors mainly used a CRIg-Ig fusion protein in their experiments to induce Treg cells and tolerance, which may be artificial. They should purify CRIg^+^macrophages and coculture them with activated Th cells to test whether the macrophages with physiological levels of CRIg can specifically induce Foxp3^+^ Tregs.

We thank the reviewer for the suggestion. We have performed the suggested experiments and included the data as [Figure 3D](#fig3){ref-type="fig"}. Our results showed that coculturing with CRIg^+^ macrophages enhanced the generation of iTreg cells in vitro, compared with CRIg^-^ macrophages.

However, we also wanted to emphasize that in this study, we focus on understanding the role of CRIg molecule. As CRIg^+^ macrophages may have other functions that are independent of CRIg.

> 2\) It was shown that CRIg-Ig promoted iTreg differentiation in vitro, but the authors should address whether CRIg^+^macrophages could directly induce pTregs in in vivo settings. This will strengthen their claims. The frequency of Tregs in the pancreas was reduced in CRIg^-/-^NOD as shown in [Figure 1C](#fig1){ref-type="fig"}. However, this experimental system does not exclude a possibility of indirect contribution of CRIg to the expansion of pTregs.

We understand that the reviewer wanted to see whether there was a direct effect of CRIg^+^ macrophages in Treg induction. We could isolate and transfer CRIg^+^ macrophages into congenically disparate recipient mice. However, we do not think this assay could address whether these transferred CRIg^+^ macrophages expand pTreg cells directly or by influencing other cells or pathways. Another caveat is that it is challenging to assess tissue engraftment of transferred macrophages, as these cells do not express CCR2 and other key chemokine receptors for tissue migration. We think that an in vitro coculture could define the direct effect of these TRMs in iTreg induction. We have performed this experiment, as it also answered the question raised in comment \#1. We have included these data as [Figure 3D](#fig3){ref-type="fig"}.

We, however, propose that genetic ablation of CRIg would provide critical clues of the role of CRIg in affecting Treg (especially pTreg) abundancy, and our results supported this notion. To further strengthen this claim, we now have specifically analyzed the proportion of Helios^-^ Tregs (largely pTregs) in various tissue sites (pancreas, colon and lung) of NOD/CRIg^-/-^and wildtype littermate controls. CRIg^+^ macrophages are present in pancreas and colon, but not in the lung ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Our data showed that Helios^-^ pTregs in pancreas and colon, but not lung, were preferentially reduced in CRIg null mutant mice, correlated with the tissue-distribution profile of CRIg^+^ macrophages. These data further supported the role of CRIg in affecting the abundancy of pTreg. We have now included these pTreg results between CRIg^-/-^and wildtype mice as [Figure 3G](#fig3){ref-type="fig"}, and added the analyses of CRIg^+^ cells in the lung in [Figure 1---figure supplement 1A, B](#fig1s1){ref-type="fig"}.

> In addition, regarding [Figure 1](#fig1){ref-type="fig"}, how did the authors investigate the percentages of CRIg^+^macrophages and each T cell population in pancreas? Additionally, the authors seemed to isolate cells from pancreatic islets selectively, but how did they do this? There seems to be no explanation for these procedures in the manuscript.

We apologize for any ambiguity in the descriptions.

For CRIg^+^ macrophages, the numbers showed in [Figure 1A](#fig1){ref-type="fig"} (right panel) were counted from immunostaining of pancreatic sections of 10-wks old NOD mice. We examined each individual islet under microscope and counted the total number of CRIg^+^ TRMs per each islet. For this measurement, we did not isolate these cells from pancreatic islets. We have now updated the descriptions to improve the clarity in the Materials and methods, figure legends and text. We here wanted to explain a bit more about why we chose such a method. Because during the development of insulitis in both mice (e.g., NOD strain) and humans, not all islets are synchronously infiltrated (there are intact islets even in long-standing diabetic patients) (Bluestone, Herold and Eisenbarth, 2010), the reasons for this heterogeneous penetrance remain poorly understood. Due to the unique peri-islet distribution of CRIg^+^ TRMs and the function of CRIg, our studies led to a model whereby CRIg^+^ macrophages form a protective barrier for each individual islet. This provided a plausible explanation to the long-standing question of why some islets are infiltrated while others are not. The dearth of CRIg^+^ TRMs at a barrier of the islet may exacerbate the infiltration.

For T cells, the "% Treg in CD4" in panel C was calculated by gating on Foxp3 fractions within CD4^+^ populations. It also reflected the ratio between Treg and Foxp3^-^ CD4 T cells. For the panel of "Ratio Treg/CD8", it meant within the pancreas of each individual mouse (depicted by each dot), the number of Treg cells divided by the number of CD8^+^ T cells. Using this analysis, it clearly highlighted the loss of balance between Treg cells and other T cells that are largely pathogenic. We have now updated the descriptions in the Materials and methods, figure legends and text for clarity.

> 3\) Relating to the above point, where do pancreatic CRIg^+^macrophages interact with activated Tconv cells and convert them into pTregs? Is there co-localization of CRIg^+^macrophages and converted Foxp3^+^ Tregs in the pancreas?

We thank the reviewers for raising this question. We performed a co-staining of CRIg and CD4 of pancreatic frozen sections from a 10-wk old NOD mice (having ongoing insulitis) to reveal whether there was cell-cell contact between CRIg^+^ TRMs and CD4 T cells. Indeed, we found cell aggregates containing both CRIg^+^ TRMs and CD4^+^ T cells, conforming the close interactions among them. We have now included the results as [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}.

Again, these data supported our model whereby CRIg^+^ macrophages form a protective barrier for each individual islet. Notably, while we were revising this manuscript, a paper published by Mohan et al. (Mohan JF, PNAS 2017. 114: E7776) suggested a similar role of peri-islet macrophages. We quote their statements here and note that one graph from their study depicts the localizations of macrophages and T cells in pancreas of NOD mice; "Suppressive roles of MFs have also been reported (Fu et al., 2012), which may be accounted for by their position as gate-keepers to islet entry in the initial phases, or by the capsule that MFs appear to form around the remaining β-cell mass in cases of established insulitis".

> 4\) In [Figure 2D](#fig2){ref-type="fig"}, CRIg-Ig binding to activated Tconv is shown, but staining intensity is marginal and not convincing. More kinetics and control cells should be taken. In addition, expression levels of CRIg on thymic, peripheral, and in vitro induced Tregs need to be examined.

We have now repeated multiple times the binding of CRIg to activated T cells at different time-points of T cell activation and different concentrations of CRIg-Ig. These new data confirmed our conclusion of that CRIg can bind to activated T cells. Consistent with the conclusion in [Figure 2A](#fig2){ref-type="fig"}, it showed that the expression of putative CRIg receptors was higher at early stage of T cell activation (the binding intensities: 12h≅24h\>\>72h). We have now replaced the original [Figure 2D](#fig2){ref-type="fig"} with these new data.

We apologize for any confusion in describing the expression of CRIg. CRIg is not expressed in T cells of any subset, or location. We have now included one panel of FACS analyses of CRIg expression in T cells, B cells and NK cells as [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}.

> 5\) With CRIg^-/-^BL6 mice, are the findings in NOD mice also the case in BL6 mice? Since macrophages from various tissues express CRIg, the authors should examine whether CRIg^-/-^mice have reduced frequencies of Tregs in mucosal tissues such as the gut, peritoneum, skin, and lung, where CRIg^+^tissue macrophages are present.

In contrast to the acceleration of autoimmunity by CRIg deficiency in NOD strain, CRIg^-/-^BL6 mice do not exhibit obvious sign of autoimmune pathology. We analyzed the percentages of Treg cells in small and large intestinal lamina propria (there is no T cells in the pancreas of B6 background) of 6-10 wks old CRIg^-/-^BL6 mice and wildtype littermate controls. Treg percentages were not affected in CRIg^-/-^mice at this age. This is to some extent reminiscent of the phenotype of PD-1^-/-^ mice, as it has been reported that PD-1 deficiency on B6 or Balb/c background only exhibited mild immunopathology only in aged mice (Nishimura H, *Immunity.* 1999. 11:141-51). However, the autoimmune pathology was markedly exacerbated after crossing to autoimmune susceptible strains (Yoshida T, PNAS 2008. 105:3533).

In NOD mice, we have now examined the percentages of pTreg cells in mucosal tissues per the reviewer's suggestion. Please refer to the answers to comment \#2.

> 6\) The rationale for the CRIg/C3 blockade experiments in [Figure 2](#fig2){ref-type="fig"} supplements is unclear. A combination of CRIg-Ig and anti-CRIg completely blocked the proliferation of T conv cells. Although the authors assume that anti-CRIg can block the binding of CRIg to C3 components, this unexplained strong effect of anti-CRIg on T cell suppression is a bit odd. Are active C3 components present in this culture medium? Why does anti-CRIg induce a sort of super agonistic effect of CRIg? On the other hand, this complete T cell proliferation arrest ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) with CRIg and anti-CRIg contradicts with other results ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}) in which T cells robustly proliferate in the presence of CRIg and anti-CRIg.

Why CRIg-Ig/anti-CRIg complex exhibited an enhanced effect? Under in vitro settings, we propose that this is an effect of cross-linking. This notion was supported by several observations: soluble CRIg-Ig did not affect T cell proliferation; a plate-bound condition is needed for CRIg-Ig to exhibit a suppressive effect on T cells. Adding anti-CRIg mAb probably further affected the conformational change of CRIg to enhance its engagement with the putative CRIg receptor. To further evaluate the possible cross-linking effect, we have performed a new experiment by coating anti-CRIg (or isotype) mAb to culture plate and adding soluble CRIg-Ig to in vitro cultured CD4 Tconv cells. Again, soluble CRIg-Ig did not suppress T cells if the plate was coated with isotype control mAb. However, in the presence of plate-bound anti-CRIg mAb, soluble CRIg-Ig now can robustly suppress T cell proliferation, further supporting a notion of cross-linking. We have now included these data as [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}.

Under in vivo settings, we asked whether anti-CRIg/CRIg-Ig complex exhibited a longer serum half-life compared with CRIg-Ig alone. To test this, we treated mice with one dose of CRIg-Ig, or equal amount of CRIg-Ig plus anti-CRIg Ab. The mice were sequentially bled 1, 3, and 7d after injections, and serum concentrations of CRIg were measured by ELISA using Abs of different isotypes and recognizing different epitopes. Clearly, it showed that the inclusion of anti-CRIg maintained higher serum concentrations of CRIg. We have now included these data as [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}.

Regarding complements in the culture medium. We used heat-inactivated serum for all cell cultures. However, it may still contain complement components, likely from bovine serum (we could not find an ELISA kit to specifically detect bovine complements). Therefore, we chose to use serum-free medium to repeat T cell proliferation and iTreg induction experiments with or without CRIg. However, deprivation of serum for longer than 24 hrs severely affected the viability of cultured T cells, making it difficult to assess the effect of CRIg. We then alternatively conducted a short-term assay in serum-free medium. Since we have demonstrated that CRIg attenuated TCR activation signaling cascades by measuring the phosphorylation of ZAP70, Erk1/2, AKT and S6. Therefore, using the same approach, except using serum-free culture medium. Indeed, CRIg-Ig could attenuate TCR activation without complements. We have now included these data in [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}.

Re the difference between [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} and [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}.That was due to the presence of TGF- b in [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}. TGF-β interferes the suppressive effect of CRIg-Ig on T cells.

> 7\) In [Figure 3E](#fig3){ref-type="fig"}, the differentiation of pTregs from Tconv was impaired in the pancreas, but not in LNs of CRIg^-/-^NOD mice which had received adoptive transfer of BDC2.5 Tconv. This is a bit odd. It is unlikely that there is enough cellular niche to allow Tconv to get activated, expand, and differentiate into pTreg in T cell-sufficient NOD mice. They should show more detailed FACS profiles, for example, the proportion of Thy1.1 (transferred) vs Thy1.2 (resident) in Foxp3^+^ Tregs in the pancreas and LNs.
>
> Also, CRIg-Ig treatment enhanced pTreg generation in pancreas but not in panLNs and ILNs in [Figure 3D](#fig3){ref-type="fig"}. The authors should discuss the reason for this result.

For [Figure 3E](#fig3){ref-type="fig"} (now became [Figure 3F](#fig3){ref-type="fig"}), in these experiments, we chose 4-wk old recipient, a time point at which insulitis just started. We used activated TCR monoclonal BDC2.5 T cells that were highly diabetogenic and had the advantages for competition with polyclonal endogenous T cells. We have now added FACS data to show the engraftments of transferred Thy1.1^+^ T cells and the fractions of them becoming GFP(Foxp3)^+^ ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Because the key point here was how much transferred Tconv cells were converted into Treg cells in the presence or absence of CRIg-Ig, we only analyzed transferred cells, not endogenous Treg cells.

Re "Why CRIg-Ig treatment enhanced pTreg generation in pancreas but not in panLNs and ILNs?"This is mainly due to that pTreg cells are primarily differentiated at tissue sites. Mice deficient for Foxp3 conserved noncoding sequence 1 (CNS1) have normal numbers of tTregs but have severe deficit of pTregs (Zheng et al., 2010). The defects are most striking at mucosal surfaces, which are the primary sites for pTreg generation. We have strengthened this statement in the text.

> 8\) Is the target molecule of CRIg on effector T cells and regulatory T cells same or different? The authors should discuss how CRIg exhibit opposite effects on the two different T cell populations.

Without knowing the cognate receptor for CRIg in Tconv or Treg cells, we here provide our postulations based on the data from the binding and functional assays. First, CRIg exhibits a coinhibitory effect on T cells. For this function, I don't think it is opposite between Tconv and Treg cells. CRIg can bind to both Tconv and Treg cells. However, the binding intensity was substantially higher in Tconv than that in Treg cells, suggesting that the putative receptor that mediates coinhibitory effect is more abundantly expressed in activated Tconv than that in Treg cells. Consistent with this, we found that under the same experimental settings CRIg more potently suppressed Tconv than Treg cells (as shown in [Author response image 1](#respfig1){ref-type="fig"}).

![](elife-29540-resp-fig1){#respfig1}

Regarding the effect of CRIg in promoting Treg generation. Our data supported that the putative receptor mediating T cell suppression is not necessarily needed for Treg differentiation by CRIg. This is because that CRIg-Ig would not suppress T cells at the late stage of T cell in vitro activation and proliferation ([Figure 2A](#fig2){ref-type="fig"}), which is very likely due to the transient expression of the receptor for CRIg in T cells. However, we did a new experiment and found that CRIg can still promote the conversion of these T cells at their late stage of in vitro activation/proliferation into Foxp3^+^ Treg cells in the presence of TGF-β. This suggested that another mechanism is involved in Treg induction. We have now included these data and also revised the discussions accordingly.

> 9\) It is hard to understand why the authors focused on environmental factors that modulate CRIg expression on TRMs in the tissues other than pancreas. Is there any relationship between CRIg levels in pancreatic TRMs and bacterial colonization or RA? How about the expression of CRIg in pancreatic TRMs after birth in wild-type and NOD mice? It is more valuable for this study to find the environmental cues that would regulate CRIg levels in pancreatic TRMs, if possible, especially during the development of type 1 diabetes.

We thank the reviewer for these comments. Related to comment \#12 below, we have now performed new experiments to dissect the connections between environmental factors (gut microbiota and RA) and CRIg^+^ TRMs in the pancreas especially during the development of T1D, as the reviewer pointed out. We have included the new data as [Figure 7E](#fig7){ref-type="fig"} and [Figure 7J](#fig7){ref-type="fig"}. Interestingly, while antibiotic treatment diminished pancreatic CRIg^+^ TRMs, blocking RA signaling in vivofailed to do so, suggesting different regulations were utilized at different tissues to maintain CRIg expression in TRMs. A recently study demonstrated that antibiotic-mediated gut microbiome perturbation accelerates development of type 1 diabetes in mice (Livanos et al., 2016). The dampened expression of CRIg in pancreatic TRMs could be one possible mechanism.

> 10\) Does CRIg bind to Treg and synergize with TGFb? Binding of CRIg to Tregs should be added (as in [Figure 2D](#fig2){ref-type="fig"} for activated T cells) along with key controls.

The promoting effect of CRIg-Ig in iTreg differentiation could be directly through enhancing TGF-β signaling or potentiating other signaling in iTregs independent of TGF- b. We have now conducted the phosphorylation assays of Smad2/3 in iTreg condition in the presence or absence of CRIg-Ig and found that CRIg-Ig did not further enhance TGF- b induced Smad2/3 phosphorylation. We have previously found that CRIg-Ig suppress the activities of AKT and S6 in T cells under iTreg condition. Therefore, CRIg-Ig does not directly affect TGF-b signaling, instead, potentiates other pathways that facilitate iTreg differentiation. We have now added the Smad2/3 phosphorylation results as [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}.

We have now demonstrated that CRIg can bind to activated Treg cells, but to a much lower level compared to that in Tconv cells. We have now included these data as [Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}.

> 11\) Treg stability depends on the methylation status of FoxP3 CNS2 region. The authors have shown that CRIg does not affect the methylation status of CNS2 site of Foxp3 yet FoxP3 expression in adoptively transferred iTregs generated with CRIg-Ig is remarkably stable. The inference from this observation is that Tregs do not need continuous cell:cell contact with CRIg-expressing macrophages to maintain FoxP3 expression and function. The authors should discuss this point.

We thank the reviewer for this comment. Our data supported this inference. As we have found that transferred iTreg cells preconditioned by CRIg were more stable even in spleen, where there was no CRIg^+^ cells. We have further strengthened this point in the Results and Discussion.

> 12\) The experiments in [Figures 6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"} are interesting and compelling. However they do not connect well with the rest of the paper. These features should have been examined in pancreatic macrophages to make [Figures 6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"} cohesive with [Figures 1](#fig1){ref-type="fig"}-5.

Please see the answers to comment \#9.
